Document:

Form of 4.30% Senior Note due 2014

 Exhibit 4.1 
 FORM OF NOTE 
 THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS
REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER
THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 
 Unless this certificate is
presented by an authorized representative of The Depository Trust Company, a limited-purpose trust company organized under the New York Banking Law (“DTC”), to the Company or its agent for registration of transfer, exchange or
payment, and any certificate issued is registered in the name of Cede & Co. or in such other name as is requested by an authorized representative of DTC (and any payment is made to Cede & Co. or to such other entity as is requested
by an authorized representative of DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the registered owner hereof, Cede & Co., has an interest herein. 
  

			
	STATE STREET CORPORATION
	4.30% Senior Notes Due 2014
		
	No. 1	  	    $500,000,000
	CUSIP 857477 AE3	  	Issue Date: May 22, 2009
	ISIN US857477AE35	  	

 State Street Corporation, a corporation duly organized and existing under the laws of The
Commonwealth of Massachusetts (herein called the “Company,” which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede & Co., or registered
assigns, the principal sum of FIVE HUNDRED MILLION Dollars ($500,000,000) on May 30, 2014, and to pay interest thereon from May 22, 2009, or from the most recent Interest Payment Date to which interest has been paid or duly provided for,
semi-annually in arrears on May 30 and November 30 in each year, commencing November 30, 2009, at the rate of 4.30% per annum, until the principal hereof is paid or made available for payment. The interest so payable, and
punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the Regular
Record Date for such interest, which shall be May 15 or November 15 (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date. Any such interest not so punctually paid or duly provided for will
forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the
payment of such Defaulted Interest to be 

  

 A-1 

 
fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or
be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully
provided in said Indenture. 
 Payment of the principal of (and premium, if any) and any such interest on this Security will be made at the
office or agency of the Company maintained for that purpose in the City of Boston, Massachusetts (the “Place of Payment”), in such coin or currency of the United States of America as at the time of payment is legal tender for
payment of public and private debts; provided that for so long as this Security is a Global Security, payment of the principal of (and premium, if any) and any interest on this Security will be made by the Paying Agent by wire transfer of
immediately available funds to a separate account of the Depositary or its nominee at the Federal Reserve Bank of New York; provided that, in the case of payments made at maturity of such Global Security, the Global Security is presented to
the Paying Agent in time for the Paying Agent to make such payments in accordance with its normal procedures. 
 Interest on this Security
will be computed on the basis of a 360-day year comprised of twelve 30-day months. In the event that an Interest Payment Date is not a Business Day, the Company will pay interest on the next day that is a Business Day, with the same force and effect
as if made on the Interest Payment Date, and without any interest or other payment with respect to the delay. If the date of maturity for this Security is not a Business Day, payment of principal and interest on this Security will be made on the
following day that is a Business Day and no interest will accrue for the period from and after such date of maturity. 
 This Security is one
of a duly authorized issue of securities of the Company (herein called the “Securities”), issued and to be issued in one or more series under an Indenture, dated as of March 11, 2009 (herein called the
“Indenture”), between the Company and U.S. Bank National Association, as trustee (herein called the “Trustee,” which term includes any successor trustee under the Indenture), and reference is hereby made to the
Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee, and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated
and delivered. This Security is one of the series designated on the face hereof, in the initial principal amount of $500,000,000. 
 The
Indenture contains provisions for defeasance at any time of the entire indebtedness of this Security or certain restrictive covenants and Events of Default with respect to this Security, in each case upon compliance with certain conditions set forth
in the Indenture. 
 If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal of the
Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture. 
  

 A-2 

 The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the
modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in
principal amount of the Securities at the time Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time
Outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by
the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not
notation of such consent or waiver is made upon this Security. 
 As provided in and subject to the provisions of the Indenture, the Holder
of this Security shall not have the right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee
written notice of a continuing Event of Default with respect to the Securities of this series, the Holders of not less than 25% in principal amount of the Securities of this series at the time Outstanding shall have made written request to the
Trustee to institute proceedings in respect of such Event of Default as Trustee and offered the Trustee reasonable indemnity, and the Trustee shall not have received from the Holders of a majority in principal amount of Securities of this series at
the time Outstanding a direction inconsistent with such request, and shall have failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing shall not apply to any suit instituted
by the Holder of this Security for the enforcement of any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein. 
 No reference herein to the Indenture and no provision of this Security or of the Indenture shall alter or impair the obligation of the Company, which is
absolute and unconditional, to pay the principal of and any premium and interest on this Security at the times, place and rate, and in the coin or currency, herein prescribed. 
 As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the Security Register,
upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any premium and interest on this Security are payable, duly endorsed by, or accompanied by a written
instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of
authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. 
  

 A-3 

 The Securities of this series are issuable only in registered form without coupons in denominations of
$2,000 and any integral multiple thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this series and of like
tenor of a different authorized denomination, as requested by the Holder surrendering the same. 
 No service charge shall be made for any
such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 
 Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat
the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary. 
 All terms used in this Security which are defined in the Indenture shall have the meanings assigned to them in the Indenture. 
 Unless the certificate of authentication hereon has been executed by the Trustee by manual signature, this Security shall not be entitled to any benefit
under the Indenture or be valid or obligatory for any purpose. 
  

 A-4 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its corporate seal.

 Dated: May 22, 2009 
 STATE STREET
CORPORATION 
  

			
	By:	 	
	Name:	 	
	Title	 	
		
	Attest:	 	

 TRUSTEE’S CERTIFICATE OF AUTHENTICATION 
 This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 
 U.S. BANK NATIONAL ASSOCIATION, as Trustee 
  

			
	By:	 	
	Authorized Officer

  

 A-5Secured Note Purchase Agreement, dated May 18, 2009

 Exhibit 10.90 
 ANESIVA, INC. 
 SECURED NOTE PURCHASE
AGREEMENT 
 THIS SECURED NOTE PURCHASE
AGREEMENT (this “Agreement”) is made as of the 18th day of May, 2009 (the “Effective Date”), by and between Anesiva, Inc., a Delaware corporation (the “Company”),
and Arcion Therapeutics, Inc. (together with its successors and assignees, “Investor”). 
 WHEREAS: 
 A. The Company has requested a loan from Investor. 
 B. Subject to the terms and conditions of this Agreement, Investor has agreed upon the terms of this Agreement to purchase from the Company, and the Company has agreed to sell to Investor, a secured promissory Note in the form set forth in
Exhibit A. 
 C. In connection with the execution of this Agreement, the Company, each of the Company’s Subsidiaries (other than
Anesiva Hong Kong Limited) (the “Subsidiary Guarantors”), and Investor are also entering into a Pledge, Security and Collateral Agent Agreement (as such may be amended, restated, supplemented or modified from time to time, the
“Security Agreement”) in the form set forth in Exhibit B. The Security Agreement, among other things, provides that the Note (as defined below) issued hereunder shall be a secured obligation under such Security Agreement.

 D. In connection with the execution of this Agreement, each of the Subsidiary Guarantors shall guaranty the obligations of the Company
arising under this Agreement and the Related Documents (as defined below) pursuant to a form of Guaranty (as such may be amended, restated, supplemented or modified from time to time, the “Guaranty”) in the form set forth in
Exhibit C. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, and for other
consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereby agree as follows: 
  

	1.	AMOUNT AND TERMS OF THE NOTE 

 Subject to the terms and conditions of this Agreement, the Company agrees to sell and issue to Investor and Investor agrees to purchase from the Company a
secured promissory Note in the form of note attached hereto as Exhibit A (as amended, restated, supplemented or otherwise modified from time to time, the (“Note”) in the aggregate principal amount equal to Two Million Dollars
($2,000,000.00) (the “Aggregate Commitment”). The Note shall not be issued at a discount. 
  

	2.	THE CLOSING 

 2.1
Closing. The closing (the “Closing”) of the purchase and sale of the Note to Investor shall take place at such time and place as the Company and Investor mutually agree upon orally or in writing. At the Closing, the Company
agrees to issue and sell to Investor and Investor agrees, subject to the satisfaction or waiver of the conditions set forth in Section 5, to purchase the Note. 

 2.2 Delivery. At the Closing: (i) Investor will deliver to the Company in immediately
available funds an amount equal to the Aggregate Commitment and (ii) the Company shall deliver to Investor a Note dated the date of such Closing in a principal amount equal to the Aggregate Commitment. 
  

	3.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

 Except as disclosed by the Company in the disclosure schedule delivered to Investor on the date hereof (the “Disclosure Schedule”), the
Company hereby represents and warrants to Investor that the representations and warranties contained in this Section 3 are true, complete and correct and accurate in all respects. The Disclosure Schedule shall be arranged in paragraphs
corresponding to the numbered and lettered paragraphs contained in this Section 3, and the disclosures in any paragraph of the Disclosure Schedule shall qualify only the corresponding paragraph of this Section 3, unless it is reasonably
clear from a reading of the disclosure that such disclosure is applicable to such other sections and subsections. 
 3.1 Organization,
Good Standing and Qualification. The Company and each of its Subsidiaries is a corporation duly organized, validly existing and in good standing under the laws of its jurisdiction of incorporation. The Company and each of the Subsidiary
Guarantors has the corporate power and authority to own and operate its properties and assets, to execute and deliver (to the extent that it is a party to such agreement) (i) this Agreement, (ii) the Note to be issued in connection with
this Agreement, (iii) the Security Agreement, (iv) any Guaranty, (v) the Subordination Agreement, and (vi) all other agreements related to this Agreement and the Note (the preceding clauses (ii) through (vi), collectively,
together with all other agreements, instruments and documents delivered from time to time in connection herewith and therewith, as any or all of the foregoing may be supplemented, restated, extended or amended from time to time, the “Related
Documents”), to issue and sell the Note and to carry out the provisions of this Agreement and the Related Documents and to carry on its business as presently conducted and as proposed to be conducted. Each of the Company and each of its
Subsidiaries is duly qualified and is authorized to do business and is in good standing as a foreign corporation in all jurisdictions in which the nature of its activities and of its properties (both owned and leased) makes such qualification
necessary, except for those jurisdictions in which failure to do so has not, or would not have, individually or in the aggregate, a material adverse effect on the business, assets, liabilities, financial condition or prospects of the Company and its
Subsidiaries (a “Material Adverse Effect”). 
 3.2 Authorization; Binding Obligations. All corporate action on the
part of the Company and each of its Subsidiaries (including the respective officers and directors) necessary for the authorization of this Agreement and the Related Documents, the performance of all obligations of the Company and its Subsidiaries
hereunder and under the Related Documents at the Closing and, the authorization, sale, issuance and delivery of the Note has been taken or will be taken prior to the Closing. This Agreement and the Related Documents, when executed and delivered and
to the extent it is a party thereto, will be valid and binding obligations of each of 

  

 2 

 
the Company and each of its Subsidiaries, enforceable against each such Person in accordance with their terms, except as limited by applicable bankruptcy,
insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights and general principles of equity that restrict the availability of equitable or legal remedies. The offer, sale and issuance
of the Note are not subject to any preemptive rights or rights of first refusal that will not have been properly waived or complied with. No vote of the stockholders of the Company is required in connection with the issuance and sale of the Note or
any of the other transactions contemplated by this Agreement and the Related Documents. 
 3.3 Liabilities. None of the Company nor
any Subsidiary has liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of any type, whether accrued, absolute, contingent, matured, unmatured or other, except for those which (i) have been reflected in the
SEC Reports or (ii) have arisen in the ordinary course of business consistent with past practices since March 31, 2009. 
 3.4
Agreements; Action. 
 (a) the Company has filed as an exhibit to an SEC Report all agreements and contracts
required to be filed by Item 601 of Regulation S-K. 
 (b) Since December 31, 2008, neither the Company nor
any of its Subsidiaries has: (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock; (ii) incurred any indebtedness for money borrowed or any other
liabilities (other than ordinary course obligations) individually in excess of Fifty Thousand Dollars ($50,000.00) or, in the case of indebtedness and/or liabilities individually less than Fifty Thousand Dollars ($50,000.00), in excess of One
Hundred Fifty Thousand Dollars ($150,000.00) in the aggregate; (iii) made any loans or advances to any person not in excess, individually or in the aggregate, of One Hundred Thousand Dollars ($100,000.00), other than ordinary course advances
for travel expenses; or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale of its inventory in the ordinary course of business. 
 (c) For the purposes of subsections (a) and (b) above, all indebtedness, liabilities, agreements, understandings,
instruments, contracts and proposed transactions involving the same Person (including Persons the Company has reason to believe are affiliated therewith) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such
subsections. 
 3.5 Obligations to Related Parties. There are no obligations of the Company or any of its Subsidiaries to officers,
directors, stockholders or employees of the Company or any of its Subsidiaries other than (a) for payment of salary for services rendered and for bonus payments; (b) reimbursement for reasonable expenses incurred on behalf of the Company
and its Subsidiaries; and (c) for other standard employee benefits made generally available to all employees (including stock option agreements outstanding under any stock option plan approved by the Board). 
  

 3 

 3.6 Changes. Since December 31, 2008, there has not been: 
 (a) any material change, except in the ordinary course of business, in the obligations of the Company or any of its Subsidiaries by
way of guaranty, endorsement, indemnity, warranty or otherwise; 
 (b) any damage, destruction or loss, whether or not
covered by insurance, that has had, or could have, individually or in the aggregate, a Material Adverse Effect; 
 (c)
any waiver not in the ordinary course of business by the Company or any of its Subsidiaries of a valuable right or of a material debt owed to it; 
 (d) any material change in any compensation arrangement or agreement with any officer or director of the Company or any of its Subsidiaries; 
 (e) any labor organization activity related to the Company or any of its Subsidiaries; or 
 (f) any arrangement or commitment by the Company or any of its Subsidiaries to do any of the acts described in subsection
(a) through (e) above. 
 3.7 Title to Properties and Assets; Liens, Etc. Each of the Company and each of its Subsidiaries
has good and marketable title to its respective properties and assets, and good title to its leasehold estates, in each case subject to no mortgage, pledge, lien, lease, encumbrance or charge, other than (a) those resulting from taxes which
have not yet become delinquent; (b) minor liens and encumbrances which do not materially detract from the value of the property subject thereto or materially impair the operations of the Company or any of its Subsidiaries; (c) those that
have otherwise arisen in the ordinary course of business and (d) the Permitted Liens. All facilities, machinery, equipment, fixtures, vehicles and other properties owned, leased or used by the Company and its Subsidiaries are in reasonably good
operating condition and repair and are reasonably fit and usable for the purposes for which they are being used. The Company and its Subsidiaries are in compliance with all material terms of each lease to which it is a party or is otherwise bound.

 3.8 Intellectual Property. 
 (a) Each of the Company and each of its Subsidiaries owns or possesses sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other
proprietary rights and processes reasonably necessary for its business as now conducted and to the Company’s knowledge, as presently proposed to be conducted (the “Intellectual Property”), without any known infringement of the
rights of others. 
 (b) Neither the Company nor any of its Subsidiaries has received any written communications
alleging that the Company or any of its Subsidiaries has violated any of the patents, trademarks, service marks, trade names, copyrights or trade secrets or other proprietary rights of any other person or entity, nor is the Company or any of its
Subsidiaries aware of any basis therefor. 
  

 4 

 3.9 Compliance with Other Instruments. Neither the Company nor any of its Subsidiaries is in
violation or default of (x) any term of its Certificate of Incorporation, Bylaws or other organizational documents or (y) of any provision of any indebtedness, mortgage, indenture, contract, agreement or instrument to which it is party or
by which it is bound or of any judgment, decree, order or writ, which violation or default, in the case of this clause (y), has had, or could have, either individually or in the aggregate, a Material Adverse Effect. The execution, delivery and
performance of and compliance with this Agreement and the Related Documents to which it is a party, and the issuance and sale of the Note by the Company will not, with or without the passage of time or giving of notice, result in any such violation,
or be in conflict with or constitute a default under any such term or provision, or result in the creation of any mortgage, pledge, lien, encumbrance or charge upon any of the properties or assets of the Company or any of its Subsidiaries or the
suspension, revocation, impairment, forfeiture or nonrenewal of any permit, license, authorization or approval applicable to the Company, its Subsidiaries, their businesses or operations or any of their assets or properties. 
 3.10 Litigation. Except as described in the SEC Reports, (i) there are no legal or governmental actions, suits, proceedings or investigations
pending and (ii) to the Company’s knowledge, there are no legal or governmental actions, suits, proceedings or investigations threatened, to which the Company or any of its Subsidiaries is or may be a party or subject or of which property
of the Company or any of its Subsidiaries is or may be the subject, or related to applicable environmental or discrimination matters, or instituted by the Securities and Exchange Commission (the “SEC”), the Financial Industry
Regulatory Authority, any state securities commission or other governmental or regulatory entity; and, to the Company’s knowledge, no labor disturbance by the employees of the Company or any of its Subsidiaries exists, or is imminent which is
reasonably expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is a party to or subject to the provisions of any injunction, judgment, decree or order of any court, regulatory body, administrative agency or
other governmental body. 
 3.11 Tax Returns and Payments. Each of the Company and each of its Subsidiaries has timely filed all tax
returns required to be filed by it. All taxes shown to be due and payable on such returns, any assessments imposed and all other taxes due and payable by the Company or any of its Subsidiaries on or before the Closing, have been paid or will be paid
prior to the time they become delinquent. Except as set forth on Schedule 3.12 to the Securities Purchase Agreement, neither the Company nor any of its Subsidiaries has been advised (a) that any of its returns have been or are being audited or
(b) of any deficiency in assessment or proposed judgment to its taxes. 
 3.12 Employees. Except as set forth on Schedule 3.13 to
the Securities Purchase Agreement, neither the Company nor any of its Subsidiaries has any collective bargaining agreements with any of its employees. There is no labor union organizing activity pending or, to the Company’s knowledge,
threatened with respect to the Company or any of its Subsidiaries. To the knowledge of the Company, no employee of the Company or any of its Subsidiaries has plans to terminate his or her employment relationship with the Company and its
Subsidiaries. No director, officer or employee of or consultant to the Company or any of its Subsidiaries is in violation of any terms of any employment contract, non-competition agreement, non-disclosure agreement, patent disclosure or assignment
agreement or other contract or agreement containing restrictive covenants relating to the right of any such director, officer, employee or consultant to be employed or engaged by the Company and its Subsidiaries because of the nature of the business
conducted or proposed to be conducted by the Company and its Subsidiaries, or relating 
  

 5 

 
to the use of trade secrets or proprietary information of others. The Company and each of its Subsidiaries is in compliance with all applicable laws, rules
and contracts relating to employment, employment practices, wages, overtime, severance pay, bonuses and terms and conditions of employment, including employee compensation matters and required contributions to managers insurance and pension funds.

 3.13 Registration Rights and Voting Rights. Except as set forth on Schedule 3.14 to the Securities Purchase Agreement, neither the
Company nor any of its Subsidiaries is presently under any obligation, and neither the Company nor any of its Subsidiaries has granted any rights, to register any of the Company’s or its Subsidiaries’ presently outstanding securities or
any of its securities that may hereafter be issued. Except as set forth on Schedule 3.14 to the Securities Purchase Agreement, to the Company’s knowledge, no stockholder of the Company or any of its Subsidiaries has entered into any agreement
with respect to the voting of equity securities of the Company or any of its Subsidiaries. 
 3.14 Compliance with Laws; Permits.
Neither the Company nor any of its Subsidiaries is in violation of any applicable statute, rule, regulation, order or restriction of any domestic or foreign government or any instrumentality or agency thereof in respect of the conduct of its
business or the ownership of its properties which has had, or would have, either individually or in the aggregate, a Material Adverse Effect. No governmental orders, permissions, consents, approvals or authorizations are required to be obtained and
no registrations or declarations are required to be filed in connection with the execution and delivery of this Agreement or any Related Documents and the issuance of the Note, except such as has been duly and validly obtained or filed, or with
respect to any filings that must be made after the Closing, as will be filed in a timely manner. Each of the Company and its Subsidiaries has all material franchises, permits, licenses and any similar authority necessary for the conduct of its
business as now being conducted by it. 
 3.15 Environmental and Safety Laws. Neither the Company nor any of its Subsidiaries is in
violation of any applicable statute, law or regulation relating to the environment or occupational health and safety, and to its knowledge, no expenditures are or will be required in order to comply with any such existing statute, law or regulation.
No Hazardous Materials (as defined below) are used or have been used, stored or disposed of by the Company or any of its Subsidiaries or, to the Company’s knowledge, by any other person or entity on any property owned, leased or used by the
Company or any of its Subsidiaries. For the purposes of the preceding sentence, “Hazardous Materials” shall mean (a) materials that are listed or otherwise defined as “hazardous” or “toxic” under any
applicable local, state, federal and/or foreign laws and regulations that govern the existence and/or remedy of contamination on property, the protection of the environment from contamination, the control of hazardous wastes or other activities
involving hazardous substances, including building materials, or (b) any petroleum products or nuclear materials. 
 3.16 Valid
Offering. Assuming the accuracy of the representations and warranties of Investor contained in this Agreement, the offer, sale and issuance of the Note will be exempt from the registration requirements of the Securities Act of 1933, as amended
(the “Securities Act”), and will have been registered or qualified (or are exempt from registration and qualification) under the registration, permit or qualification requirements of all applicable state securities laws. 

 

 6 

 3.17 SEC Reports. The Company has filed all proxy statements, reports and other documents required
to be filed by it under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since January 1, 2008. The Company has furnished or made available to Investor copies of: (i) its Annual Report on Form 10-K for
its fiscal year ended December 31, 2008; (ii) its Quarterly Report on Form 10-Q for its fiscal quarter ended March 31, 2009 and (iii) the Form 8-K filings which it has made during the fiscal 2009 to date (collectively, the
“SEC Reports” and, together with this Agreement and the Disclosure Schedule, the “Disclosure Materials”). Each SEC Report was, at the time of its filing, in compliance in all material respects with the requirements
of its respective form and none of the SEC Reports, nor the financial statements (and the Note thereto) included in the SEC Reports, as of their respective filing dates, contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. As of the date hereof, the Company satisfies the registrant requirements set forth in
General Instruction I.A. to Form S-3 for the use of a Registration Statement on Form S-3. 
 3.18 Internal Accounting Controls. The
Company and its Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations;
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with U.S. generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in
accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Company and designed such disclosures controls and procedures to ensure that material information relating to the Company and
its Subsidiaries is made known to the certifying officers by others within those entities, particularly during the period in which the Company’s Form 10-K or 10-Q, as the case may be, is being prepared. 
 3.19 No Integrated Offering. Neither the Company, nor any of its Subsidiaries or Affiliates, nor any Person acting on its or their behalf, has
directly or indirectly made any offers or sales of any security or solicited any offers to buy any security under circumstances that would cause the offering of the Note pursuant to this Agreement to be integrated with prior offerings by the Company
for purposes of the Securities Act which would prevent the Company from selling the Note pursuant to Rule 506 under the Securities Act, or any applicable exchange-related stockholder approval provisions, nor will the Company or any of its Affiliates
or Subsidiaries take any action or steps that would cause the offering of the Note to be integrated with other offerings. 
 3.20 Food and
Drug Administration. 
 (a) Neither the Company nor any of its Subsidiaries is debarred under the Generic Drug
Enforcement Act of 1992 or otherwise excluded from or restricted in any manner from participation in, any government program related to pharmaceutical products and, to the knowledge of the Company, does not employ or use the services of any
individual who is debarred or otherwise excluded or restricted. 
  

 7 

 (b) Each of the product candidates of the Company and its Subsidiaries is being,
and at all times has been, developed, tested, manufactured and stored, as applicable, in substantial compliance in all material respects with all applicable statutes, laws or regulations. 
 (c) Neither the Company nor any of its Subsidiaries is subject to any pending or, to the knowledge of the Company, threatened,
investigation by: (A) the FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,” set forth in 56 Fed. Reg. 46191 (September 10, 1991); (B) Department of Health and Human Services
Officer of Inspector General or Department of Justice pursuant to the Federal Anti-Kickback Statute (42. U.S.C. Section 1320a-7(b)) or the Civil False Claims Act (31 U.S.C. Section 3729 et seq.); or (C) any equivalent statute
of any other country. Neither the Company nor any of its Subsidiaries, nor, to the knowledge of the Company, (1) any officer or employee of the Company or any of its Subsidiaries, (2) any authorized agent of the Company or any of its
Subsidiaries or (3) any principal investigator or sub-investigator of any clinical investigation sponsored by the Company or any of its Subsidiaries has, in the case of each of (1) through (3) on account of actions taken for or on
behalf of the Company or any of its Subsidiaries, been convicted of any crime under 21 U.S.C. Section 335a(a) or any similar state or foreign statute, law or regulation or under 21 U.S.C. Section 335a(b) or any similar state or foreign
statute, law or regulation. 
 (d) No clinical trial of a product of the Company or any of its Subsidiaries has been
suspended, put on hold or terminated prior to completion. 
 3.21 Accounts Receivable; Accounts Payable. 
 (a) All of the accounts receivable of the Company and its Subsidiaries are reflected on the Company’s balance sheet (the
“Balance Sheet”) at December 31, 2008 (the “Balance Sheet Date”) in accordance with U.S. generally accepted accounting principles and represent bona fide completed sales made in the ordinary course of business,
are valid claims and, to the Company’s best knowledge, are not subject to any set offs or counterclaims and are fully collectible in the normal course of business after deducting the reserve set forth in the Company’s Balance Sheet. Since
the Balance Sheet Date, the Company and its Subsidiaries have collected their respective accounts receivable in the ordinary course and in a manner that is consistent with their prior practices. Neither the Company nor any of its Subsidiaries has
any accounts receivable or loans receivable from any Person that is an Affiliate of the Company or any of its Subsidiaries or from any director, officer or employee of the Company or any of its Subsidiaries or any Affiliate thereof. 
 (b) All of the accounts payable and notes payable of the Company and each of its Subsidiaries arose in bona fide arms’ length
transactions in the ordinary course of business, and no such account payable or note payable is delinquent by more than sixty (60) days in its payment. Since the Balance Sheet Date, the Company and its Subsidiaries have paid their respective
accounts payable in the ordinary course and in a manner that is consistent with their respective prior practices. As of the date hereof, neither the Company nor any of its Subsidiaries have any accounts payable to any Person that is an Affiliate of
the Company or any of its Subsidiaries or to any director, officer or employee of the Company or any of its Subsidiaries or any Affiliate thereof. 
  

 8 

 3.22 Foreign Corrupt Practices Act. Neither the Company nor any of its Subsidiaries has engaged,
nor has any officer, director, employee or agent of the Company or any of its Subsidiaries engaged, in any act or practice that would constitute a violation of the Foreign Corrupt Practices Act of 1977, or any rules or regulations promulgated
thereunder. There is not now, and there never has been, any employment by the Company or any of its Subsidiaries by, any governmental or political official in any country in the world. 
 3.23 Reserved. 
 3.24 Change of
Control Benefits. Except under the Securities Purchase Agreement or the Indenture, neither the consummation of any Change of Control (either alone or in connection with any other event, including any termination of employment or service), will
(i) result in any payment (including any bonus, golden parachute or severance payment) becoming due to any employee or consultant of the Company or any of its Subsidiaries; (ii) result in any forgiveness of indebtedness owing by any
employee or consultant of the Company or any of its Subsidiaries to the Company or any of its Subsidiaries or, to the knowledge of the Company, owing by any employee of the Company or any of its Subsidiaries to any third party; (iii) materially
increase the benefits payable by the Company or any of its Subsidiaries, or (iv) result in any acceleration of the time of payment or vesting of any such benefits. 
 3.25 Full Disclosure. Neither this Agreement, the Related Documents or the exhibits and schedules hereto and thereto or any other information provided by the Company or its agents to Investor in connection with
the transactions contemplated by this Agreement and the Related Documents contain any untrue statement of a material fact nor omit to state a material fact necessary in order to make the statements contained herein or therein, in light of the
circumstances in which they are made, not misleading. 
  

	4.	REPRESENTATIONS AND WARRANTIES OF INVESTOR 

 Investor represents and warrants to the Company, as of the date hereof, as follows: 
 4.1 Purchase for Own Account. Investor represents that it is acquiring the Note solely for its own account and beneficial interest for investment
and not for sale or with a view to distribution of the Note or any part thereof, has no present intention of selling (in connection with a distribution or otherwise), granting any participation in or otherwise distributing the same. Investor is not
a registered broker-dealer under Section 15 of the Exchange Act or an entity engaged in a business that would require it to be so registered as a broker-dealer. Investor further represents that it has full power and authority to enter into this
Agreement and the Related Documents to which it is a party and all such agreements, when executed and delivered by Investor, shall constitute valid and legally binding obligations of Investor, enforceable against Investor in accordance with their
respective terms except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and other laws of general application affecting enforcement of creditor’s rights generally and as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies. 
  

 9 

 4.2 Information and Sophistication. Investor has had an opportunity to ask questions and receive
answers from the Company regarding the terms and conditions of the offering of the Note. Investor further represents that it has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risk of
this investment. The foregoing, however, shall not be deemed in any way to limit the scope of the representations and warranties of the Company in Section 3 or the ability of Investor to rely thereupon. 
 4.3 Ability to Bear Economic Risk. Investor acknowledges that investment in the Note involves a high degree of risk, and represents that it is
able, without materially impairing its financial condition, to hold the Note for an indefinite period of time and to suffer a complete loss of the investment. 
 4.4 Further Limitations on Disposition. Investor understands that the Note are characterized as “restricted securities” for the purposes of federal securities laws and are being acquired in a
transaction not involving a public offering, have not been registered under the Securities Act and that such securities may only be resold only if registered pursuant to the provisions of the Securities Act or if an exemption from registration is
available and that the Company is not required to register the Note under the Securities Act. Investor acknowledges that it is familiar with Rule 144 promulgated under the Securities Act and understands the resale limitation imposed thereby.

 4.5 Experience. Investor is an “accredited investor” as such term is defined in Rule 501 under the Securities Act.

 4.6 No Governmental Review. Investor understands that no United States federal or state agency or any other government or
governmental agency has passed on or made any recommendation or endorsement of the Note or the fairness or suitability of the investment in the Note nor have such authorities passed upon or endorsed the merits of the offering of the Note.

 4.7 Certain Trading Activities. Other than with respect to the transactions contemplated herein, since the time that Investor was
first contacted by the Company or any other Person regarding the transactions contemplated hereby, neither Investor nor any Affiliate of Investor which (i) had knowledge of the transactions contemplated hereby, (ii) has or shares
discretion relating to Investor’s investments or trading or information concerning Investor’s investments, including in respect of the Note, and (y) is subject to Investor’s review or input concerning such Affiliate’s
investments or trading (collectively, “Trading Affiliates”) has directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding with Investor or Trading Affiliate, effected or agreed to effect any
transactions in the securities of the Company (including, without limitation, any Short Sales (as defined below) involving the Company’s securities). Notwithstanding the foregoing, in the case of an Investor and/or Trading Affiliate that is,
individually or collectively, a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of Investor’s or Trading Affiliate’s assets and the portfolio managers have no direct knowledge of the investment
decisions made by the portfolio managers managing other portions of Investor’s or Trading Affiliate’s assets, the 

  

 10 

 
representation set forth above shall apply only with respect to the portion of assets managed by the portfolio managers that have knowledge about the
financing transaction contemplated by this Agreement. Other than to other Persons party to this Agreement and to advisors, Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the
existence and terms of this transaction). For purposes of this Section 4.7, “Short Sales” include, without limitation, (i) all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the
Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the Exchange
Act) and similar arrangements (including on a total return basis), and (ii) sales and other transactions through non-U.S. broker dealers or foreign regulated brokers. 
 4.8 Regulation M. Investor is aware that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of the
Company’s Common Stock and other activities with respect to the Company’s Common Stock by Investor. 
 4.9 California Securities
Laws. Investor acknowledges and agrees that the sale of the Note has not been qualified with the Commissioner of Corporations of the State of California and the issuance of such securities or the payment or receipt of any part of the
consideration for such securities prior to such qualification is unlawful, unless the sale of securities is exempt from qualification by Section 25100, 25102 or 25105 of the California Corporations Code. The rights of all parties to this
agreement are expressly conditioned upon such qualification being obtained, unless the sale is so exempt. 
 4.10 Legends. Each Note
may bear a form of the following legends: 
 (a) “THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “ACT”) OR ANY STATE SECURITIES LAW. NO SALE, PLEDGE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR AN EFFECTIVE REGISTRATION STATEMENT
RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAW.” 
 (b) Any legend required by applicable corporations or securities laws of any state. 
  

	5.	CONDITIONS TO CLOSING OF INVESTOR 

 Investor’s obligation to lend money to the Company at the Closing is subject to the satisfaction or waiver, each at the discretion of Investor, of
the following conditions: 
 5.1 Representations and Warranties. The representations and warranties of the Company contained in
Section 3 shall be true and correct on and as of the Closing. 
  

 11 

 5.2 Performance. The Company and its Subsidiaries shall have performed and complied with all
covenants, agreements, obligations and conditions contained in this Agreement and the Related Documents that are required to be performed or complied with by it on or before the Closing, including the filing of UCC-1 financing statements and
appropriate filings with the Patent and Trademark Office. 
 5.3 Reserved. 
 5.4 Security Agreement. The Company, the Subsidiary Guarantors and Investor shall have executed and delivered the Security Agreement and such
agreement shall be in full force and effect. 
 5.5 Guaranty and Subordination Agreement. Each of the Subsidiary Guarantors shall have
executed and delivered a Guaranty and Subordination Agreement for the benefit of Investor and each such agreement shall be in full force and effect. 
 5.6 Consents and Approvals. All consents, approvals, waivers, authorizations, licenses or orders of, registrations, qualifications, designations, declarations or filings with, or notice to any governmental
entity or any other Person necessary to be obtained, made or given as of the Closing in connection with the transactions contemplated hereby shall have been duly obtained, made or given and shall be in full force and effect, without the imposition
upon the Company of any condition, restriction or required undertaking. 
 5.7 Proceedings. All corporate and other proceedings taken
or required to be taken by the Company and the Subsidiary Guarantors and in connection with the transactions contemplated hereby, including the approvals by the Board and the Special Committee, shall be reasonably satisfactory in form and substance
to Investor and all documents incident thereto shall have been executed and delivered to Investor or their counsel, and shall be reasonably satisfactory in form and substance to Investor and their counsel. In addition, the Company shall have
delivered good standing certificates and tax good standing certificates with respect to the Company and its Subsidiaries from each jurisdiction in which such Person is incorporated. 
 5.8 Legal Opinion. Investor shall have received from Cooley Godward Kronish LLP, corporate counsel for the Company, an opinion, dated as of the
Closing, in substantially the form agreed to as of the date hereof. 
 5.9 Secretary’s Certificate. The Secretary of the Company
shall have delivered to Investor at the Closing a certificate certifying: (a) the Company’s Certificate of Incorporation as in effect as of the Closing; (b) the Bylaws of the Company as in effect as of the Closing;
(c) resolutions of the Board approving this Agreement, the Related Documents and the transactions contemplated hereby and thereby; and (d) resolutions of the Special Committee of the Board recommending to the Board this Agreement, the
Related Documents and the transactions contemplated hereby and thereby. 
 5.10 Due Diligence. Investor shall be satisfied in its sole
discretion at the Closing with the diligence review of the business, legal, accounting and other investigations undertaken by Investor and their advisors and agents with respect to the Company. 
  

 12 

 5.11 Financing Statements. The Company shall have authorized Investor (as defined in the Security
Agreement), for the benefit of Investor, to prepare and file such financing statements and other instruments, including, without limitation, the filing of UCC-1 financing statements and appropriate filings with the Patent and Trademark Office
(collectively, “Financing Statements”), as Investor shall require in order to perfect and maintain the continued perfection of the first priority security interest created by the Security Agreement and the other applicable Related
Documents and the Company hereby authorizes Investor to prepare and file such Financing Statements. 
 5.12 No Event of Default. No
event shall have occurred and be continuing or would result from the consummation of the Closing that would constitute an Event of Default. 
 5.13 Letter Agreement. The Company and Investor shall have executed and delivered a letter agreement dated as of the date of the Closing. 
  

	6.	REGISTRATION, TRANSFER AND EXCHANGE OF NOTE 

 6.1 [Intentionally Omitted]. 
 6.2 Transfer. Subject to Section 4, Investor shall be entitled to transfer its Note in any manner permitted by applicable law and to the registration of such transfer by the Company in the name of such transferee or transferees
as shall be specified by Investor. In the event of a proposed transfer, the transferring Investor shall give written notice to the Company of Investor’s intention to effect such transfer. Each such notice shall describe the manner and
circumstances of the proposed transfer in sufficient detail, and shall, if the Company so requests, be accompanied by either: (i) a written opinion of legal counsel, who shall be reasonably satisfactory to the Company, addressed to the Company
and reasonably satisfactory in form and substance to the Company’s counsel, to the effect that the proposed transfer of the Note may be effected without registration under the Securities Act or (ii) a “no action” letter from the
SEC to the effect that the transfer of such Note without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto, whereupon the holder of such restricted securities shall be entitled to
transfer such restricted securities in accordance with the terms of the notice delivered by such holder to the Company; provided, however, that no opinion or “no action” letter need be obtained with respect to a transfer to:
(a) an affiliate (as such term is defined in the Securities Act) of Investor; (b) a partner, active or retired, of Investor; (c) the estate of any such partner; or (d) the spouse, children, grandchildren or spouse of such
children or grandchildren of any holder or to trusts for the benefit of Investor or such Persons. In connection with any transfer in accordance with this Section 6.2 and at all other times hereunder, Investor shall be entitled to surrender its
Note to the Company together with a written request for the issuance of one or more new Note, specifying the denomination or denominations thereof and, in the case of a transfer of a Note, the name and address of the new transferee or transferees.
As soon as reasonably practicable, the Company shall issue a new Note bearing the same interest rate and in the same form, in the same aggregate principal amount as the Note being surrendered in the name of Investor. Each such new Note shall be
dated and bear interest from the date to which interest shall have been paid on the surrendered Note or dated the date of the surrendered Note if no interest shall have been paid thereon. Each Note presented or surrendered for reissuance and
registration of a new Note shall be endorsed, or, in the case of a transfer of a Note, shall be accompanied by a duly executed written instrument of transfer in an appropriate form. The applicable Investor shall be responsible for any transfer taxes
associated with the 

  

 13 

 
transfer of any Note. Any transferee, by its acceptance of a Note in its name (or the name of its nominee), shall be deemed to have made the representations
set forth in Section 4. Notwithstanding the foregoing, any such transferee shall execute and deliver a counterpart of this Agreement, the Security Agreement and the Guaranty to the Company and Investor, in form and substance satisfactory to
Investor, and, by delivering such counterpart, such transferee shall be deemed to agree to be bound by the provisions of this Agreement, the Security Agreement, the Guaranty and the other Related Documents. 
 6.3 Issuance of Notes. The Company and Investor may treat the Person in whose name any Note is issued as the absolute owner of such Note for all
purposes, and all payments in respect of a Note made to any such Person or upon such Person’s order shall satisfy and discharge the liability of the Company or Investor (as the case may be) on such Note to the extent of the sum or sums so paid.

 6.4 Mutilated, Destroyed, Lost or Stolen Note. In case the Note shall become mutilated or defaced, or be destroyed, lost or stolen,
the Company shall execute and deliver a new Note of like principal amount in exchange and substitution for the mutilated or defaced Note, or in lieu of and in substitution for the destroyed, lost or stolen Note. In the case of a mutilated or defaced
Note, Investor shall surrender such Note to the Company. In the case of any destroyed, lost or stolen Note, Investor shall furnish to the Company: (i) evidence to the Company’s satisfaction of the destruction, loss or theft of such Note
and (ii) such security or indemnity as may be reasonably required by the Company. 
  

	7.	AFFIRMATIVE COVENANTS 

 The Company hereby covenants that so long as any portion of the Note remains outstanding: 
 7.1 Notices. The Company shall
notify Investor within five (5) Business Days after the Board of Directors or senior officers of the Company has knowledge or becomes aware of the occurrence of: (i) any action, suit or proceeding before any arbitrator, court or
governmental department, domestic or foreign, pending, or to the Company’s knowledge, threatened against or affecting the Company or any Subsidiary of the Company, which if adversely determined could have a Material Adverse Effect,
(ii) any material dispute or default by the Company, any of its Subsidiaries or any other party under any joint venture, partnering, distribution, cross-licensing, strategic alliance, collaborative research or manufacturing, license or similar
agreement which would reasonably be expected to have a Material Adverse Effect, or (iii) any default or Event of Default hereunder or under any Related Document. 
 7.2 Existence. The Company shall maintain and preserve the existence, present form of business and all rights and privileges necessary or desirable in the normal course of business of the Company and its
Subsidiaries; and keep all of the property of the Company and its Subsidiaries in good working order and condition, ordinary wear and tear excepted. 
 7.3 Insurance. The Company shall (and shall cause its Subsidiaries to) obtain and keep in force insurance in such amounts and types as is usual in the type of business conducted by the Company or such
Subsidiary, as applicable, with insurance carriers having a policyholder 

  

 14 

 
rating of not less than “A” and financial category rating of Class VII in “Best’s Insurance Guide,” unless otherwise approved by
Investor. Such insurance policies must be in form and substance reasonably satisfactory to Investor, and shall list Investor as an additional insured or loss payee, as applicable, on endorsement(s) in form reasonably acceptable to Investor. The
Company shall furnish to Investor such endorsements, and upon Investor’s request, copies of any or all such policies. If no Event of Default has occurred and is continuing, proceeds payable under any casualty policy will, at the Company’s
option, be payable to the Company to replace the property subject to the claim, provided that such replacement property shall be deemed part of the Collateral (as defined in the Security Agreement). If an Event of Default has occurred and is
continuing, then, at Investor’s option, the proceeds payable under any casualty policy will be payable to Investor and applied toward satisfaction of the Obligations. 
 7.4 Accounting Records. On and after the date of this Agreement, the Company shall (and shall cause its Subsidiaries to) maintain adequate books,
accounts and records, and prepare all financial statements in accordance with U.S. generally accepted accounting principles, and in compliance with the regulations of any governmental or regulatory authority having jurisdiction over the Company,
such Subsidiary or the business of the Company or such Subsidiary. 
 7.5 Compliance with Laws. The Company shall (and shall cause its
Subsidiaries to) comply with all laws, rules, regulations applicable to, and all orders and directives of any governmental or regulatory authority having jurisdiction over, the Company, such Subsidiary or the business of the Company or such
Subsidiary, and with all material agreements to which the Company or such Subsidiary is a party, except where the failure to so comply would not have a Material Adverse Effect. 
 7.6 Taxes and Other Liabilities. The Company shall (and shall cause its Subsidiaries to) pay all of Indebtedness (as defined below) of the Company
or such Subsidiary when due; pay all taxes and other governmental or regulatory assessments before delinquency or before any penalty attaches thereto, except as may be contested in good faith by the appropriate procedures and for which the Company
shall maintain appropriate reserves; and timely file all required tax returns. 
 7.7 Special Collateral Covenants. The Company shall
(and shall cause its Subsidiaries to): 
 (a) do all things reasonably necessary to maintain, preserve, protect and
keep all Collateral in good working order and saleable condition, ordinary wear and tear excepted, deal with the Collateral in all ways as are considered good practice by owners of like property and use the Collateral lawfully and, to the extent
applicable, only as permitted by the insurance policies of the Company and its Subsidiaries; 
 (b) maintain, or cause
to be maintained, complete and accurate Records (as defined below) relating to the Collateral; 
  

 15 

 (c) upon reasonable prior notice at reasonable times during normal business hours
with reasonable prior notice, permit Investor’s officers, employees, representatives and agents to inspect the Collateral and to discuss the Collateral and the Records relating thereto with the officers and employees of the Company and its
Subsidiaries, and, in the case of any Rights to Payment (as defined below), with any Person which is or may be obligated thereon; 
 (d) at the request of Investor, firmly affix a decal, stencil or other marking to designated items of Equipment (as defined below), indicating thereon the security interest of Investor; and 
 (e) obtain and maintain such acknowledgments, consents, waivers and agreements from the owner, lienholder, mortgagee and landlord
with respect to any real property on which Collateral is located as Investor may reasonably require, all in form and substance satisfactory to Investor. 
 7.8 Financing Statements and Other Actions. The Company shall execute and deliver to Investor all financing statements, notices and other documents (including, without limitation, any filings with the Patent
and Trademark Office) from time to time as may be reasonably requested by Investor to maintain a first priority perfected security interest in the Collateral in favor of Investor; and perform such other acts, and execute and deliver to Investor such
additional conveyances, assignments, agreements and instruments, as Investor may at any time reasonably request in connection with the administration and enforcement of this Agreement or Investor’s rights, powers and remedies hereunder.

 7.9 Reserved. 
 7.10 Reserved. 
 7.11 Further Assurances. The Company shall, and shall cause any of its Subsidiaries to, take such
actions as are necessary or as Investor may reasonably request from time to time (including the execution and delivery of joinders and/or guaranties to this Agreement and any other applicable Related Documents, termination statements, deposit
account control agreements, securities account control agreement and other documents, the filing or recording of any of the foregoing, and the delivery of stock certificates and other collateral with respect to which perfection is obtained by
possession) to ensure that the obligations of the Company and its Subsidiaries hereunder and under the other Related Documents are secured by substantially all of the assets, equity securities and personal property of the Company and its
Subsidiaries (whether now existing or promptly upon the acquisition or creation thereof after the date hereof). 
 7.12 Additional
Subsidiaries. If any additional Subsidiary of the Company is formed or acquired after the Effective Date, the Company shall, within three Business Days after such Subsidiary is formed or acquired, (i) notify Investor and the Lenders
thereof, (ii) cause such Subsidiary to execute and become a party to a guaranty of the obligations hereunder, the Security Agreement or any other security agreement, and such other Related Documents in favor of Investor as Investor may request
and (iii) pledge one hundred percent (100%) of the Capital Stock of such Subsidiary (except that the Company or any of its Subsidiaries shall not be required to pledge more than 65% of the outstanding voting Capital Stock of any Subsidiary
organized under the laws of any jurisdiction outside the United States of America) to Investor pursuant to the Security Agreement or any other security agreement. The Company agrees to 

  

 16 

 
provide such evidence as Investor shall request as to the perfection and priority status of each security interest and Lien created by such security
documents. The Company shall dispose of the notes outstanding pursuant to the Securities Purchase Agreement at a price equal to one (1) times the price per share of the Company’s Common Stock as quoted on Nasdaq at the close of trading on
the date of the Closing. 
  

	8.	NEGATIVE COVENANTS 

 The Company hereby covenants that so long as any portion of the Note remains outstanding: 
 8.1 Restrictions on Fundamental
Changes. Except with the prior written approval of Investor or pursuant to the terms of the letter agreement, dated as of the date of the Closing, between the Company and Investor, as the same may be amended, restated or otherwise modified in
writing from time to time, neither the Company nor any of its Subsidiaries will merge with or consolidate into, or acquire all or substantially all of the assets of, any Person, or sell, transfer, lease or otherwise dispose of (whether in one
transaction or in a series of transactions) all or substantially all or any material amount of its assets or commence any Insolvency Proceeding with respect to itself; or a custodian, receiver, trustee, assignee for the benefit of creditors, or
other similar official shall be appointed to take possession, custody or control of the properties of the Company or any Subsidiary, and such involuntary Insolvency Proceeding, petition or appointment is acquiesced to by the Company or such
Subsidiary as applicable or is not dismissed within sixty (60) days; or dissolve or terminate of the business of the Company or any Subsidiary. 
 8.2 Change of Control. The Company will not permit a Change of Control to occur. 
 8.3
Distributions. Except with the prior approval of Investor, neither the Company nor any of its Subsidiaries will declare or pay any dividends in respect of their Capital Stock, or purchase, redeem, retire or otherwise acquire for value any of
their Capital Stock now or hereafter outstanding, return any capital to their stockholders as such, or make any distribution of assets to their stockholders as such, or permit any of its Subsidiaries to purchase, redeem, retire or otherwise acquire
for value any stock of the Company, except that the Company may: (i) declare and deliver dividends and distributions payable solely in Common Stock of the Company and (ii) purchase shares or options of employees, consultants and other
service providers in accordance with stock option, stock issuance or other stock purchase plans and employment contracts of the Company. 
 8.4 Indebtedness. Except with the prior approval of Investor, neither the Company nor any Subsidiary will create, incur, assume or otherwise become liable for or suffer to exist any Indebtedness (including under existing indentures,
loan agreements and other facilities), other than the following (“Permitted Indebtedness”): (i) Indebtedness for borrowed money to Investor hereunder; (ii) Guaranty and any other guarantees by any Subsidiaries of the
Company of Indebtedness of the Company incurred hereunder; (iii) Indebtedness consisting of guarantees resulting from endorsement of negotiable instruments for collection by the Company in the ordinary course of business; (iv) Indebtedness
incurred for the purpose of financing the acquisition of equipment provided that the principal amount therefore does not exceed the purchase price of such equipment; and (v) Indebtedness consisting of accounts payable to trade creditors for
goods and services and expenses (other than for borrowed money), in each case incurred in the ordinary course of business as presently conducted. 
  

 17 

 8.5 Liens. Except with the prior written approval of Investor, neither the Company nor any
Subsidiary will create, incur, assume or suffer to exist any Lien upon or with respect to any of its properties, revenues or assets, whether now owned or hereafter acquired except for any of the following (“Permitted Liens”):
(i) Liens in favor of Investor in respect of the indebtedness hereunder and under the Security Agreement and second priority Liens in connection with the Securities Purchase Agreement; (ii) Liens for taxes, fees, assessments or other
governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings and which are adequately reserved for in accordance with U.S. generally accepted accounting principles; (iii) Liens of
materialmen, mechanics, warehousemen, carriers or employees or other like Liens arising in the ordinary course of business and securing obligations either not delinquent or being contested in good faith by appropriate proceedings; (iv) Liens
consisting of deposits or pledges to secure the payment of worker’s compensation, unemployment insurance or other social security benefits or obligations, or to secure the performance of bids, trade contracts, leases, public or statutory
obligations, surety or appeal bonds or other obligations of a like nature incurred in the ordinary course of business; (v) easements, rights of way, servitudes or zoning or building restrictions and other minor encumbrances on real property and
irregularities in the title to such property which do not in the aggregate materially impair the use or value of such property or risk the loss or forfeiture of title thereto; (vi) non-exclusive licenses granted in the ordinary course of
business and consistent with past practices; and (vii) Liens upon or in any equipment acquired or held by the Company or any Subsidiary to secure the purchase price of such equipment or indebtedness incurred solely for the purpose of financing
the acquisition of such equipment, provided that the Lien is confined solely to the equipment so acquired and accessions thereon. 
 8.6
Capital Expenditures. Except with the prior written approval of Investor, neither the Company nor any Subsidiary shall make any Capital Expenditures in excess of One Hundred Thousand Dollars ($100,000.00) in any one instance or series of related
instances. 
 8.7 Use of Proceeds. Except with the prior written approval of Investor, neither the Company nor any Subsidiary shall
use any proceeds from the Note hereunder, directly or indirectly, for the purposes of repaying any pre-existing debt of the Company or any of its Subsidiaries outside the ordinary course of business. Notwithstanding the foregoing, the Company shall
use $609,000 of the proceeds of the issuance of the Note within one (1) Business Day of the date of the Closing to pay amounts due to Hospira. 
 8.8 Affiliate Transactions. Except with the prior written approval of Investor, neither the Company nor any Subsidiary shall enter into any transaction, including the purchase, sale or exchange of property or the rendering of any
services or debt financing, with any Affiliate or enter into, assume or suffer to exist any employment or consulting contract with any Affiliate, except a transaction or contract which is in the ordinary course of the business of the Company or such
Subsidiary, as applicable, and which is upon fair and reasonable terms not less favorable to the Company or such Subsidiary, as applicable, than it would obtain in a comparable arm’s length transaction with a Person not an Affiliate.

  

 18 

 8.9 Investments. Except with the prior written approval of Investor, neither the Company nor any
Subsidiary shall make loans to, investments in or purchase securities of any Person or Subsidiary, or otherwise extend credit to any Person or Subsidiary (other than extensions of trade credit arising from the sale of goods or services in the
ordinary course of business) or loans or advances to employees for travel expenses as approved by the Board, in amounts in excess of Ten Thousand Dollars ($10,000.00) individually or Twenty-Five Thousand Dollars ($25,000.00) in the aggregate.

 8.10 Sales of Assets. Except with the prior written approval of Investor or pursuant to the terms of the letter agreement, dated as
of the date of the Closing, between the Company and Investor, as the same may be amended, restated or otherwise modified in writing from time to time, neither the Company nor any Subsidiary shall sell, transfer, lease, license or otherwise dispose
of (a “Transfer”) any of its assets except: (i) non-exclusive licenses of Intellectual Property in the ordinary course of business consistent with industry practice; (ii) Transfers of worn-out, obsolete or surplus property
(each as determined by the Company in its reasonable judgment); (iii) Transfers of Inventory (as defined below); (iv) Transfers constituting Permitted Liens; and (v) Transfers of assets (other than Intellectual Property) for fair
consideration and in the ordinary course of its business consistent with past practices. 
 8.11 Other Business. Except with the prior
written approval of Investor, neither the Company nor any Subsidiary shall engage in any material line of business other than the business that the Company or such Subsidiary conducts or intends to conduct as of the Effective Date. 
 8.12 Deposit Accounts and Securities Accounts. Except with the prior written approval of Investor, neither the Company nor its Subsidiaries shall
maintain any Deposit Accounts or accounts holding securities owned by the Company or any Subsidiary except for Deposit Accounts and securities/investment accounts, in each case, with respect to which the Company or the Subsidiary, as applicable, and
Investor shall have taken such action as Investor reasonably deem necessary to obtain a perfected first security interest therein, including the execution and delivery of control agreements in favor of Investor. 
 8.13 Documents of Title. Except with the prior written approval of Investor or with respect to Permitted Liens, neither the Company nor any
Subsidiary shall sign or authorize the signing of any financing statement or other document naming the Company or such Subsidiary, as applicable, as debtor or obligor, or acquiesce or cooperate in the issuance of any bill of lading, warehouse
receipt or other document or instrument of title with respect to any Collateral, except those negotiated to Investor, or those naming Investor as secured party. 
 8.14 Debt or Equity Offering. Except with the prior written approval of Investor, neither the Company nor any of its Subsidiaries shall issue, deliver, sell, authorize, grant, pledge or otherwise encumber any
shares of Capital Stock or any securities convertible into shares of Capital Stock, or any debt or convertible debt securities, or subscriptions, rights, warrants or options to acquire any shares of Capital Stock or any securities convertible into
shares of Capital Stock, or enter into other agreements or commitments of any character obligating it to issue any such shares, debt or convertible securities, other than (i) the issuance, delivery and/or sale of shares of the Company’s
Common Stock pursuant to the exercise of stock options therefor outstanding as of the date of this Agreement; and (ii) the issuance or delivery of shares of the Company’s Common Stock pursuant to the exercise of warrants outstanding on the
date of this Agreement. 
  

 19 

 8.15 Certain Agreements on Rights to Payment. Except with the prior written approval of Investor
or as done in the ordinary course of business, neither the Company nor any Subsidiary shall make any material discount, credit, rebate or other reduction in the original amount owing on a Rights to Payment or accept in satisfaction of a Rights to
Payment less than the original amount thereof. 
 8.16 Modifications Organizational Documents. Except with the prior written approval
of Investor, neither the Company nor any Subsidiary shall amend, modify or change its articles of incorporation (or corporate charter or other similar organizational documents) or its bylaws (or other similar documents) in any manner adverse in any
respect to the rights or interests of Investor. 
 8.17 Modification or Prepayment of Indebtedness. Except with the prior written
approval of Investor, neither the Company nor any Subsidiary shall (i) cancel, forgive, repay, prepay, redeem, purchase, defease or otherwise satisfy in any manner, or make any payment in violation of any subordination terms of, any
Indebtedness incurred pursuant to any indenture or the Securities Purchase Agreement, or any other Indebtedness that is contractually subordinated in right of payment to the Note, or (ii) amend, modify or change in any manner any term or
condition of any such Indebtedness, provided, however, that the Securities Purchase Agreement and the other Subordinated Debt Documents (as defined in the Subordination Agreement) may be amended from time to time to the extent explicitly permitted
by the Subordination Agreement. 
  

	9.	EVENTS OF DEFAULT; ACCELERATION 

 9.1 Events of Default. The occurrence of any of the following, upon written notice by Investor to the Company (which notice shall be waived if the
Company fails to deliver notice of such Event of Default pursuant to Section 7.1), shall constitute an “Event of Default.” Upon the occurrence and during the continuation of an Event of Default that has not been cured within
the applicable period of time or waived by Investor in accordance with the terms hereof, (1) all sums of unpaid principal and interest on the Note and any Obligations and other amounts due and owing under this Agreement or any Related Document
immediately shall become due and payable (including, in the case where the underling Event of Default would trigger the Company’s obligations set forth in Section 8.2 hereof, the sums due pursuant to Section 8.2) and (2) Investor
shall have the right to exercise any other right or remedy provided by contract or applicable law: 
 (a) the Company
shall fail to pay any principal or interest due under the Note, or fail to pay any fees or other charges when due under this Agreement or any of the Related Documents, and such failure continues for three (3) Business Days or more after the
same first becomes due; 
 (b) any representation or warranty made, or financial statement, certificate or other
document provided, by the Company or any Subsidiary under this Agreement or any Related Document shall prove to have been false or misleading in any material respect when made or deemed made herein; 
  

 20 

 (c) any registration statement, proxy statement, report or other document filed by
the Company under the Securities Act or the Exchange Act shall contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading; 
 (d) the Company or any Subsidiary shall admit its inability to pay its
debts generally as they become due or shall commence any Insolvency Proceeding with respect to itself; an involuntary Insolvency Proceeding shall be filed against the Company or any Subsidiary, or a custodian, receiver, trustee, assignee for the
benefit of creditors, or other similar official shall be appointed to take possession, custody or control of the properties of the Company or any Subsidiary, and such involuntary Insolvency Proceeding, petition or appointment is acquiesced to by the
Company or such Subsidiary as applicable or is not dismissed within sixty (60) days; or the dissolution or termination of the business of the Company or any Subsidiary; 
 (e) the Company or any Subsidiary shall be in default beyond any applicable period of grace or cure under any other agreement
involving the borrowing of money, the issuance of debt securities, the purchase of property, the advance of credit or any other monetary liability of any kind to any Investor or to any other Person that results in the acceleration of payment of such
obligation in an amount in excess of One Hundred Thousand Dollars ($100,000.00); 
 (f) any governmental or regulatory
authority shall take any judicial or administrative action, or any defined benefit pension plan maintained by the Company or any Subsidiary shall have any unfunded liabilities, any of which, in the reasonable judgment of Investor, would reasonably
be expected to have a Company Material Adverse Effect; 
 (g) any sale, transfer or other disposition of all or a
substantial or material part of the assets of the Company or any Subsidiary (other than any sale, transfer or other disposition of all or a substantial or material part of any products or assets of the Company pursuant to the terms of the letter
agreement, dated as of the date of the Closing, between the Company and Investor, as the same may be amended, restated or otherwise modified in writing from time to time), including, without limitation, to any trust or similar entity, shall occur,
except where such transaction is consented to by Investor; 
 (h) any judgment(s) singly or in the aggregate in excess
of One Hundred Thousand Dollars ($100,000.00) shall be entered against the Company or any Subsidiary that remain unsatisfied, unvacated or unstayed pending appeal for forty-five (45) or more days after entry thereof; 
 (i) the Company or any Subsidiary shall fail to perform or observe any covenant contained in this Agreement; 
 (j) reserved; 
  

 21 

 (k) there shall be a Material Adverse Effect on the Company and its Subsidiaries
after the Closing (for the avoidance of doubt, the departure of key members of the Company’s management shall constitute a Material Adverse Effect) or the Collateral shall be impaired; 
 (l) the Company or any Subsidiary shall fail to perform or observe any covenant or agreement contained in this Agreement or any
Related Document (other than a covenant that is dealt with specifically elsewhere in this Article 9) and, if capable of being cured, the breach of such covenant is not cured within thirty (30) days after the sooner to occur of the
Company’s receipt of notice of such breach from Investor or the date on which such breach first becomes known to any officer of the Company; provided, however, that if such breach is not capable of being cured within such thirty
(30)-day period and the Company timely notifies Investor of such fact and the Company diligently pursues such cure, then the cure period shall be extended to the date requested in the Company’s notice but in no event more than ninety
(90) days from the initial breach; provided, further, that such additional sixty (60)-day opportunity to cure shall not apply in the case of any failure to perform or observe any covenant which has been the subject of a prior
failure within the preceding one hundred eighty (180) days or which is a willful and knowing breach by the Company or any Subsidiary; 
 (m) an “Event of Default” shall have occurred under the Securities Purchase Agreement or any indenture to which the Company or any Subsidiary is party; and 
 (n) The Company shall fail to perform or observe any of its obligations in the letter agreement, dated as of the date of the
Closing, between the Company and Investor, as the same may be amended, restated or otherwise modified in writing from time to time. 
 Notwithstanding the
foregoing, or anything to the contrary contained in this Agreement, the Company may repay the Obligations in full (but not in part) with the proceeds of a Change of Control, debt financing or equity financing and, provided the Obligations are repaid
in full concurrently (and in any event on the same Business Day) with the closing or funding of such Change of Control, debt financing or equity financing, no Event of Default shall occur solely as a result of such Change of Control, debt financing
or equity financing. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, will impair any such right, power or remedy of such
non-breaching or non-defaulting party nor will it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor will any waiver of any single breach or
default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on
the part of any party of any provisions or conditions of this Agreement, must be in writing and will be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to
any party, will be cumulative and not alternative. 
 9.2 Remedies Upon Default. (a) Upon the occurrence and during the
continuance of an Event of Default described in Section 9.1(c), each of (i) the unpaid principal amount of and accrued interest on the Note and (ii) all other Obligations shall automatically become immediately due and payable, without
presentment, demand, protest or other requirements of any kind, all of 

  

 22 

 
which are hereby expressly waived by the Company, and (b) upon the occurrence and during the continuance of any other Event of Default, Investor shall
be entitled to, at its option, exercise any or all of the rights and remedies available to a secured party under the UCC or any other applicable law, and exercise any or all of their rights and remedies provided for in this Agreement and in any
Related Document. The obligations of the Company under this Agreement shall continue to be effective or be reinstated, as the case may be, if at any time any payment of any Obligations is rescinded or must otherwise be returned by a Investor upon,
on account of or in connection with, the insolvency, bankruptcy or reorganization of the Company, any Subsidiary or otherwise, all as though such payment had not been made. 
 9.3 Sale of Collateral. In addition to any other rights set forth in this Agreement or any of the Related Documents, upon the occurrence
and during the continuance of an Event of Default, Investor may sell all or any part of the Collateral, at public or private sales, to themselves, a wholesaler, retailer or investor, for cash, upon credit or for future delivery, and at such price or
prices as Investor may deem commercially reasonable. To the extent permitted by law, the Company hereby specifically waives all rights of redemption and any rights of stay or appraisal that it has or may have under any applicable law in effect from
time to time. Any such public or private sales shall be held at such times and at such place(s) as Investor may determine. In case of the sale of all or any part of the Collateral on credit or for future delivery, the Collateral so sold may be
retained by Investor until the selling price is paid by the purchaser, but Investor shall not incur any liability in case of the failure of such purchaser to pay for the Collateral and, in case of any such failure, such Collateral may be resold.
Investor may, instead of exercising their power of sale, proceed to enforce their security interest in the Collateral by seeking a judgment or decree of a court of competent jurisdiction. Without limiting the generality of the foregoing, if an Event
of Default is in effect: 
 (a) Subject to the rights of any third parties, Investor may, in compliance with applicable
law, license, or sublicense, whether general, special or otherwise, and whether on an exclusive or non-exclusive basis, any Copyrights, Patents, Trademarks or other Intellectual Property included in the Collateral throughout the world for such term
or terms, on such conditions and in such manner as Investor shall in their sole discretion determine; 
 (b) Investor
may (without assuming any obligations or liability thereunder), at any time and from time to time, enforce (and shall have the exclusive right to enforce) against any licensee or sublicensee all rights and remedies of the Company in, to and under
any Copyright Licenses, Patent Licenses, Trademark Licenses or other Intellectual Property and take or refrain from taking any action under any thereof, and the Company hereby releases Investor from, and agrees to hold Investor free and harmless
from and against any claims arising out of, any lawful action so taken or omitted to be taken with respect thereto other than claims arising out of an Investor’s gross negligence or willful misconduct; and 
 (c) Upon request by Investor, the Company will execute and deliver to Investor a power of attorney, in form and substance
reasonably satisfactory to Investor, for the implementation of any lease, assignment, license, sublicense, grant of option, sale or other disposition of a Copyright, Patent, Trademark or other Intellectual Property. In the event of any such
disposition pursuant to this clause (c), the Company shall supply its know-how and expertise 

  

 23 

 
relating to the products or services made or rendered in connection with Patents, the manufacture and sale of the products bearing Trademarks and its
customer lists and other records relating to such Copyrights, Patents, Trademarks or other Intellectual Property and to the distribution of said products, to Investor. 
 9.4 Company’s Obligations Upon Default. Upon the request of Investor after the occurrence and during the continuance of an Event of Default, the Company will: 
 (a) Assemble and make available to Investor the Collateral at such place(s) as Investor shall reasonably designate, segregating all
Collateral so that each item is capable of identification; and 
 (b) Subject to the rights of any lessor, permit
Investor, by Investor’s officers, employees, agents and representatives, to enter any premises where any Collateral is located, to take possession of the Collateral, to complete the processing, manufacture or repair of any Collateral, and to
remove the Collateral, or to conduct any public or private sale of the Collateral, all without any liability of Investor for rent or other compensation for the use of the Company’s premises. 
  

	10.	RESERVED. 

  

	11.	INDEMNIFICATION 

 The
Company hereby agrees to indemnify Investor and its directors, officers, employees, agents, counsel, Affiliates and other advisors (each an “Indemnified Person”) against, and hold each of them harmless from, any and all liabilities,
obligations, losses, claims, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever, including the reasonable fees and disbursements of counsel to an Indemnified Person (including allocated
costs of internal counsel), that may be imposed on, incurred by or asserted against any Indemnified Person (i) in any way relating to or arising out of this Agreement or any of the Related Documents, the use or intended use of the proceeds of
the Note, or the transactions contemplated hereby or thereby; (ii) the breach or default by the Company or any of its Subsidiaries of any representation, warranty, covenant or agreement of the Company or any of its Subsidiaries contained in
this Agreement or any of the Related Documents and (iii) with respect to any investigation, litigation or other proceeding relating to any of the foregoing, irrespective of whether the Indemnified Person shall be designated a party thereto (the
“Indemnified Liabilities”); provided, however, that the Company shall not be liable to any Indemnified Person for any portion of such Indemnified Liabilities to the extent that they are found by a final decision of a
court of competent jurisdiction to have resulted from such Indemnified Person’s gross negligence or willful misconduct. If and to the extent that the foregoing indemnification is for any reason held unenforceable, the Company agrees to make the
maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities that is permissible under applicable law. 
  

 24 

	12.	MISCELLANEOUS 

 12.1 Binding
Agreement. The terms and conditions of this Agreement shall inure to the benefit of and be enforceable by the Company and Investor and its respective successors and assigns. The Company may not assign, transfer, hypothecate or otherwise convey
its rights, benefits, obligations or duties hereunder without the prior express written consent of Investor. Any such purported assignment, transfer, hypothecation or other conveyance by the Company without the prior express written consent of
Investor shall be void. Nothing in this Agreement, express or implied, is intended to confer upon any third party any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 12.2 Governing Law; Venue; Arbitration; Dispute Resolution. 
 (a) This Agreement shall be governed by and construed according to the laws of the State of California, without regard to conflict
of law principles thereof. The Company hereby (i) submits to the exclusive jurisdiction of the courts of the County of San Francisco, State of California and the Federal courts of the United States sitting in the Northern District of the State
of California for the purpose of any action or proceeding arising out of or relating to this Agreement and the Related Documents; (ii) agrees that all claims in respect of any such action or proceeding may be heard and determined in such
courts; (iii) irrevocably waives (to the extent permitted by applicable law) any objection that it now or hereafter may have to the laying of venue of any such action or proceeding brought in any of the foregoing courts, and any objection on
the ground that any such action or proceeding in any such court has been brought in an inconvenient forum; and (iv) agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by
suit on the judgment or in any other manner permitted by law. 
 (b) The parties agree that any dispute, controversy or
claim (including any counterclaim) (each, a “Dispute”) arising out of or relating to this Agreement or any Related Documents shall be finally resolved by confidential binding arbitration in San Francisco County, California as the
sole and exclusive method of resolving such dispute, controversy or claim. Any Dispute shall be settled by arbitration under the rules then in effect of JAMS/Endispute conducted by a single arbitrator reasonably acceptable to the parties. The
arbitrator shall have no power to amend this Agreement or any Related Documents. The arbitrator shall issue an award in writing (including an explanation of the grounds for such award) as promptly as practicable that shall be final and binding on
the parties. Judgment upon any award thus obtained may be entered in any court having jurisdiction thereof. No action at law or in equity based upon any claim arising out of or related to this Agreement or any Related Documents shall be instituted
in any court by any party except (a) an action to compel arbitration pursuant to this Section 12.2(b); or (b) an action to enforce an award obtained in an arbitration proceeding in accordance with this Section 12.2(b). Pending
the submission to arbitration and thereafter until the arbitrator publishes its award, each party shall, except in the event of termination, continue to perform all its obligations under this Agreement and the Related Documents without prejudice to
a final adjustment in accordance with the award. 
 12.3 Counterparts. This Agreement may be executed in two or more counterparts,
including counterparts transmitted by facsimile, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 12.4 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
  

 25 

 12.5 Notices. Any notice required or permitted under this Agreement shall be given in writing and
shall be deemed effectively given upon personal delivery, overnight courier, facsimile or upon deposit with the United States Post Office, postage prepaid, addressed to the Company, or to Investor at its address shown on the signature pages hereto,
or at such other address as such party may designate by ten (10) days advance written notice to the other party. 
 12.6 Entire
Agreement. This Agreement, the Related Documents and the exhibits and schedules hereto and thereto constitute the full and entire understanding and agreement among the parties with regard to the subjects hereof, and supersede any prior
agreements among the parties regarding the subject matter hereof. No party shall be liable or bound to any other in any manner by any representations, warranties, covenants and agreements except as specifically set forth herein. 
 12.7 Amendments and Waivers. Any term of this Agreement, the Security Agreement, the Guaranty, the Note and the other Related Documents may be
amended and the observance of any term of this Agreement, the Security Agreement, the Guaranty, the Note and the other Related Documents (other than the Subordination Agreement) may be waived (either generally or in a particular instance and either
retroactively or prospectively), with the written consent of the Company and Investor. Any amendment or waiver effected in accordance with this Section 12.7 shall be binding upon Investor and each other holder of any Note purchased under this
Agreement at the time outstanding, each future holder of all such Notes and the Company. 
 12.8 Maximum Interest. Notwithstanding
anything to the contrary in this Agreement or any Related Documents, in no event whatsoever shall the aggregate of all amounts deemed interest hereunder, under the Note or under any other Related Documents and charged or collected pursuant to the
terms of this Agreement, the Note or such Related Document exceed the highest rate permissible under any law which a court of competent jurisdiction shall, in a final determination, deem applicable hereto or thereto. If any provisions of this
Agreement, the Note or any other Related Documents are in contravention of any such law, such provisions shall be deemed amended to conform thereto (the “Maximum Rate”). If at any time, the amount of interest paid hereunder, under
the Note or any other Related documents is limited by the Maximum Rate, and the amount at which interest accrues hereunder or thereunder shall remain at the Maximum Rate, until such time as the aggregate interest paid hereunder or thereunder equals
the amount of interest that would have been paid had the Maximum Rate not applied. 
 12.9 Severability. Whenever possible, each
provision of this Agreement and the Related Documents shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement or any of the Related Documents is held to be prohibited by or
invalid under applicable law in any jurisdiction, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating any other provision of this Agreement or the Related Documents. To the extent that any
Obligations otherwise paid or payable by the Company to any Investor hereunder or under any of the Related Documents shall have been finally adjudicated to exceed the maximum amount permitted by applicable law, Investor shall be entitled to the
maximum amount allowable under applicable law. 
  

 26 

 12.10 Expenses. The Company shall pay all costs and expenses, including attorneys’ fees
(including allocated costs of internal counsel), fees, costs and expenses of accountants, advisors and consultants and costs of settlement, incurred by the Collateral Agent and Investor in connection with (i) the preparation, negotiation,
execution, delivery and administration of this Agreement and the Related Documents or any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated),
(ii) creating, maintaining and perfecting Liens in favor of the Collateral Agent, for the benefit of Investor, including filing and recording fees and expenses; (iii) in connection with the enforcement or protection of its rights and
remedies in connection with this Agreement and the Related Documents, and (iv) in enforcing any Obligations of or in collecting any payments due from the Company or any of its Subsidiaries hereunder or under the Related Documents (including in
connection with the sale of, collection from, or other realization upon any of the Collateral or the enforcement of this Agreement and the Related Documents) or in connection with any refinancing or restructuring of the credit arrangements provided
under this Agreement in the nature of a “work-out” or pursuant to any insolvency or bankruptcy proceedings. 
  

	13.	DEFINITIONS 

 The
definitions appearing in this Agreement shall be applicable to both the singular and plural forms of the defined terms: 
 “Account” means
any “account,” as such term is defined in the UCC, now owned or hereafter acquired by the Company or any Subsidiary or in which the Company or any Subsidiary now holds or hereafter acquires any interest and, in any event, shall include,
without limitation, all accounts receivable, book debts and other forms of obligations (other than forms of obligations evidenced by Chattel Paper, Documents or Instruments) now owned or hereafter received or acquired by or belonging or owing to the
Company or any Subsidiary (including, without limitation, under any trade name, style or division thereof) whether arising out of goods sold or services rendered by the Company or any Subsidiary or from any other transaction, whether or not the same
involves the sale of goods or services by the Company or any Subsidiary (including, without limitation, any such obligation that may be characterized as an account or contract right under the UCC) and all of the rights of the Company or any of its
Subsidiaries in, to and under all purchase orders or receipts now owned or hereafter acquired by it for goods or services, and all of the rights of the Company or any of its Subsidiaries to any goods represented by any of the foregoing (including,
without limitation, unpaid seller’s rights of rescission, replevin, reclamation and stoppage in transit and rights to returned, reclaimed or repossessed goods), and all monies due or to become due to the Company or any Subsidiary under all
purchase orders and contracts for the sale of goods or the performance of services or both by the Company or any Subsidiary or in connection with any other transaction (whether or not yet earned by performance on the part of the Company or any
Subsidiary), now in existence or hereafter occurring, including, without limitation, the right to receive the proceeds of said purchase orders and contracts, and all collateral security and guarantees of any kind given by any Person with respect to
any of the foregoing. 
  

 27 

 “Affiliate” means any Person which directly or indirectly controls, is controlled by or is under common
control with such Person. “Control,” “controlled by” and “under common control with” mean direct or indirect possession of the power to direct or cause the direction of management or policies (whether
through ownership of voting securities, by contract or otherwise); provided, that control shall be conclusively presumed when any Person or affiliated group directly or indirectly owns five percent (5%) or more of the securities having ordinary
voting power for the election of directors of a corporation. 
 “Business Day” means any day other than a Saturday, Sunday or other day on
which commercial banks in San Francisco, California or New York City, New York are authorized or required by law to close. 
 “Capital
Expenditures” shall mean capital expenditures of the Company and its Subsidiaries determined and consolidated in accordance with U.S. generally accepted accounting principles, excluding expenditures made in connection with the replacement,
substitution or restoration of assets to the extent financed with insurance proceeds, cash awards arising from a taking by eminent domain or condemnation or cash proceeds of asset dispositions reinvested in replacement assets. 
 “Capital Stock” means (a) with respect to any Person that is a corporation, any and all shares, interests or equivalents in capital stock (whether
voting or nonvoting, and whether common or preferred) of such corporation and (b) with respect to any Person that is not a corporation, any and all partnership, membership, limited liability company or other equity interests of such Person
(including all economic, voting and other rights related thereto); and in each case, any and all warrants, rights or options to purchase any of the foregoing. 
 “Cash and Cash Equivalents” means, as at any date of determination: (i) cash; (ii) marketable securities (a) issued or directly and unconditionally guaranteed as to interest and principal by the United
States government or (b) issued by any agency of the United States the obligations of which are backed by the full faith and credit of the United States, in each case maturing within one year after such date; (iii) marketable direct
obligations issued by any state of the United States of America or any political subdivision of any such state or any public instrumentality thereof, in each case maturing within one year after such date and having, at the time of the acquisition
thereof, investment grade rating from either Standard & Poor’s (“S&P”) or Moody’s Investor Service, Inc. (“Moody’s”); (iv) commercial paper maturing no more than one year from the
date of creation thereof and having, at the time of the acquisition thereof, a rating of at least A-1 from S&P or at least P-1 from Moody’s; (v) certificates of deposit or bankers’ acceptances maturing within one year after such
date and issued or accepted by any commercial bank organized under the laws of the United States of America or any state thereof or the District of Columbia that (a) is at least “adequately capitalized” (as defined in the regulations
of its primary Federal banking regulator) and (b) has Tier 1 capital (as defined in such regulations) of not less than U.S. $100,000,000; and (vi) shares of any money market mutual fund that (a) has at least 95% of its assets invested
continuously in the types of investments referred to in clauses (ii) and (iii) above, (b) has net assets of not less than U.S. $500,000,000, and (c) has an investment grade rating from either S&P or Moody’s. 

 

 28 

 “Change of Control” means the occurrence of any of the following: 
 (a) any transaction or series of related transactions resulting in the sale or issuance of securities or any rights to securities of the Company
representing in the aggregate more than fifty percent (50%) of the Company’s issued and outstanding voting securities, on a fully diluted basis, or any transaction or series of related transactions resulting in the sale, transfer,
assignment or other conveyance or disposition of any securities or any rights to securities of the Company by any holder or holders thereof representing in the aggregate more than fifty percent (50%) of the issued and outstanding voting
securities of the Company; 
 (b) a merger, consolidation, reorganization, recapitalization or share exchange (whether or not the Company is
the surviving and continuing entity) in which the stockholders or equityholders of the Company immediately prior to such transaction receive, in exchange for securities of the Company owned by them (whether alone or together with cash, property or
other securities), cash, property or securities of the resulting or surviving entity and as a result thereof Persons who were holders of voting securities of the Company immediately prior to such transaction hold less than fifty percent
(50%) of the issued and outstanding Capital Stock of the resulting or surviving entity entitled to vote in the election of directors, managers or similar governing body or otherwise; 
 (c) a sale, transfer, exclusive license, exclusive partnering arrangement or other disposition in a single transaction or series of related transactions
of fifty percent (50%) or more of the assets of the Company and its Subsidiaries, on a consolidated basis, other than sales of inventory in good faith to customers for fair value in the ordinary course of business and dispositions of obsolete
equipment not used or useful in the business of the Company and its Subsidiaries; 
 (d) a sale, transfer, exclusive license, exclusive
partnering arrangement or other disposition in a single transaction or series of related transactions of the Company’s Adlea assets; 
 (e) the Company or any Subsidiary shall fail to pay or admit its inability to pay its debts generally as they become due or shall commence any Insolvency Proceeding with respect to itself; an involuntary Insolvency Proceeding shall be filed
against the Company or any Subsidiary, or a custodian, receiver, trustee, assignee for the benefit of creditors, or other similar official shall be appointed to take possession, custody or control of the properties of the Company or any Subsidiary,
and such involuntary Insolvency Proceeding, petition or appointment is acquiesced to by the Company or such Subsidiary as applicable or is not dismissed within sixty (60) days; or the dissolution or termination of the business of the Company or
any Subsidiary; and 
 (f) the failure of the Company to own and control, directly or indirectly, through one or more wholly-owned
Subsidiaries, one hundred percent (100%) of the issued and outstanding Capital Stock of its Subsidiaries. 
 “Chattel Paper” means any
“chattel paper,” as such term is defined in the UCC, now owned or hereafter acquired by the Company or any Subsidiary or in which the Company or any Subsidiary now holds or hereafter acquires any interest. 
  

 29 

 “Copyright License” means any written agreement granting any right to use any Copyright or Copyright
registration now owned or hereafter acquired by the Company or any Subsidiary or in which the Company or any Subsidiary now holds or hereafter acquires any interest. 
 “Copyrights” means all of the following now owned or hereafter acquired by the Company or any Subsidiary or in which the Company or any Subsidiary now holds or hereafter acquires any interest:
(i) all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or of any other country; (ii) all registrations, applications and recordings in the United States Copyright Office or
in any similar office or agency of the United States, any State thereof or any other country; (iii) all continuations, renewals or extensions thereof; and (iv) any registrations to be issued under any pending applications. 
 “Deposit Accounts” means any “deposit accounts,” as such term is defined in the UCC, now owned or hereafter acquired by the Company or any
Subsidiary or in which the Company or any Subsidiary now holds or hereafter acquires any interest. 
 “Documents” means any
“documents,” as such term is defined in the UCC, now owned or hereafter acquired by the Company or any Subsidiary or in which the Company or any Subsidiary now holds or hereafter acquires any interest. 
 “Equipment” means any “equipment,” as such term is defined in the UCC, now owned or hereafter acquired by the Company or any Subsidiary or in
which the Company or any Subsidiary now holds or hereafter acquires any interest and any and all additions, substitutions and replacements of any of the foregoing, wherever located, together with all attachments, components, parts, equipment and
accessories installed thereon or affixed thereto. 
 “Indebtedness” of any Person means at any date, without duplication and without regard
to whether matured or unmatured, absolute or contingent: (i) all obligations of such Person for borrowed money; (ii) all obligations of such Person evidenced by bonds, debentures, note or other similar instruments; (iii) all
obligations of such Person to pay the deferred purchase price of property or services, except trade accounts payable arising in the ordinary course of business; (iv) all obligations of such Person as lessee under capital leases; (v) all
obligations of such Person to reimburse or prepay any bank or other Person in respect of amounts paid under a letter of credit, banker’s acceptance or similar instrument, whether drawn or undrawn; (vi) all obligations of such Person to
purchase securities that arise out of or in connection with the sale of the same or substantially similar securities; (vii) all obligations of such Person to purchase, redeem, exchange, convert or otherwise acquire for value any Capital Stock
of such Person or any warrants, rights or options to acquire such Capital Stock, now or hereafter outstanding, except to the extent that such obligations remain performable solely at the option of such Person; (viii) all obligations to
repurchase assets previously sold (including any obligation to repurchase any accounts or chattel paper under any factoring, receivables purchase or similar arrangement); (ix) obligations of such Person under interest rate swap, cap, collar or
similar hedging arrangements; and (x) all obligations of others of any type described in clause (i) through clause (ix) above guaranteed by such Person. 
 “Indenture” means the Senior Debt Indenture and the Supplemental Indenture to Indenture, each dated April 2, 2009, by and between the Company and The Bank of New York Mellon Trust Company, N.A.,
as amended by the Second Supplemental Indenture to Indenture on April 28, 2009 (collectively, the “Indenture”). 
  

 30 

 “Insolvency Proceeding” means with respect to a Person: (a) any case, action or proceeding before
any court or other governmental authority relating to bankruptcy, reorganization, insolvency, liquidation, receivership, dissolution, winding-up or relief of debtors with respect to such Person or (b) any general assignment for the benefit of
creditors, composition, marshalling of assets for creditors, or other, similar arrangement in respect of such Person’s creditors generally or any substantial portion of its creditors, undertaken under federal, state or foreign law, including
the Bankruptcy Code, but in each case, excluding any avoidance or similar action against such Person commenced by an assignee for the benefit of creditors, bankruptcy trustee, debtor in possession or other representative of another Person or such
other Person’s estate. 
 “Instruments” means any “instrument,” as such term is defined in the UCC, now owned or hereafter
acquired by the Company or any Subsidiary or in which the Company or any Subsidiary now holds or hereafter acquires any interest. 
 “Inventory”
means any “inventory,” as such term is defined in the UCC, wherever located, now owned or hereafter acquired by the Company or any Subsidiary or in which the Company or any Subsidiary now holds or hereafter acquires any interest, and,
in any event, shall include, without limitation, all inventory, goods and other personal property that are held by or on behalf of the Company or any Subsidiary for sale or lease or are furnished or are to be furnished under a contract of service or
that constitute raw materials, work in process or materials used or consumed or to be used or consumed in the business of the Company or any Subsidiary, or the processing, packaging, promotion, delivery or shipping of the same, and all finished
goods, whether or not the same is in transit or in the constructive, actual or exclusive possession of the Company, any Subsidiary or is held by others for the account of the Company or any Subsidiary, including, without limitation, all goods
covered by purchase orders and contracts with suppliers and all goods billed and held by suppliers and all such property first may be in the possession or custody of any carriers, forwarding agents, truckers, warehousemen, vendors, selling agents or
other Persons. 
 “knowledge” means the knowledge of the Company’s officers and other manager-level employees, and it shall be deemed
that such persons shall have made due and diligent inquiry of such matter in question. 
 “Lien” means any mortgage, deed of trust, pledge,
hypothecation, assignment for security, security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention
agreement, any lease in the nature of a security interest, and the filing of any financing statement (other than a precautionary financing statement with respect to a lease that is not in the nature of a security interest) under the UCC or
comparable law of any jurisdiction. 
 “Obligations” means all loans, advances, debts, liabilities and obligations, howsoever arising, owed
by the Company or any Subsidiary to Investor of every kind and description (whether or not evidenced by any note or instrument and whether or not for the payment of money), now 

  

 31 

 
existing or hereafter arising under or pursuant to the terms of this Agreement, the Note and each of the Related Documents, including, all interest, fees,
charges, expenses, attorneys’ fees and costs and accountants’ fees and costs chargeable to and payable by the Company or any Subsidiary hereunder and thereunder, in each case, whether direct or indirect, absolute or contingent, due or to
become due, and whether or not arising after the commencement of a proceeding under Title 11 of the United States Code (11 U.S.C. Section 101 et seq.), as amended from time to time (including post-petition interest) and whether or not
allowed or allowable as a claim in any such proceeding. 
 “Patent License” means any written agreement granting any right with respect to
any invention on which a Patent is in existence now owned or hereafter acquired by the Company or any Subsidiary or in which the Company or any Subsidiary now holds or hereafter acquires any interest. 
 “Patents” means all of the following property now owned or hereafter acquired by the Company or any Subsidiary or in which the Company or any Subsidiary
now holds or hereafter acquires any interest: (a) all letters patent of, or rights corresponding thereto in, the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights
corresponding thereto in, the United States or any other country, including, without limitation, registrations, recordings and applications in the Patent and Trademark Office or in any similar office or agency of the United States, any State thereof
or any other country; (b) all reissues, continuations, continuations-in-part or extensions thereof; (c) all petty patents, divisionals and patents of addition; and (d) all patents to be issued under any such applications. 

“Person” means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited
liability company, institution, public benefit corporation, other entity or government (whether federal, state, county, city, municipal, local, foreign or otherwise, including any instrumentality, division, agency, body or department thereof).

 “Records” means all of the computer programs, software, hardware, source codes and data processing information of the Company and its
Subsidiaries, all written documents, books, invoices, ledger sheets, financial information and statements of the Company and its Subsidiaries, and all other writings concerning the business of the Company and its Subsidiaries. 
 “Rights to Payment” means all of the accounts, instruments, contract rights, documents, chattel paper and all other rights to payment of the Company and
its Subsidiaries, including, without limitation, the Accounts, all negotiable certificates of deposit and all rights to payment under any Patent License, any Trademark License or any commercial or standby letter of credit. 
 “Securities Purchase Agreement” means that certain Securities Purchase Agreement, dated January 20, 2009, by and among Anesiva, Inc., Sofinnova
Venture Partners VII, L.P., Alta California Partners III, L.P., Alta Embarcadero Partners III, LLC, Alta Partners VIII, LP, CMEA Ventures VII, L.P., CMEA Ventures VII (Parallel), L.P., InterWest Partners VIII, LP, InterWest Investors VIII, LP, and
InterWest Investors Q VIII, LP, as amended by that certain Amendment to Securities Purchase Agreement, dated April 1, 2009, by and among Anesiva, Inc. and Sofinnova Venture Partners VII, L.P., Alta California Partners III, L.P., Alta
Embarcadero Partners III, LLC, 

  

 32 

 
Alta Partners VIII, LP, CMEA Ventures VII, L.P., CMEA Ventures VII (Parallel), L.P., InterWest Partners VIII, LP, InterWest Investors VIII, LP, and InterWest
Investors Q VIII, LP, as amended, restated, supplemented or otherwise modified from time to time in accordance with the Subordination Agreement. 
 “Subordination Agreement” means that certain Subordination Agreement dated as of May 18, 2009 by and among each of the creditors party thereto, Investor, Company and AlgoRx Pharmaceuticals, Inc., as amended, restated,
supplemented or otherwise modified from time to time. 
 “Subsidiary” means with respect to any Person, (a) any corporation (or similar
entity under foreign law) of which an aggregate of more than fifty percent (50%) of the outstanding Capital Stock having ordinary voting power to elect a majority of the board of directors (or equivalent body) of such corporation (irrespective
of whether, at the time, Capital Stock of any other class or classes of such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, owned legally or beneficially by
such Person or one or more Subsidiaries of such Person, or with respect to which any such Person has the right to vote or designate the vote of more than fifty percent (50%) of such Capital Stock whether by proxy, agreement, operation of law or
otherwise, and (b) any partnership, limited liability company, association, joint venture, trust or other entity in which such Person and/or one or more Subsidiaries of such Person shall have an interest (whether in the form of voting or
participation in profits or capital contribution) of more than fifty percent (50%) or of which any such Person is a general partner or managing member or may exercise the powers of a general partner or managing member. Unless the context
otherwise requires, each reference to a Subsidiary shall be a reference to a Subsidiary of the Company. 
 “Trademark License” means any
written agreement granting any right to use any Trademark or Trademark registration now owned or hereafter acquired by the Company or any of its Subsidiaries or in which the Company or any of its Subsidiaries now holds or hereafter acquires any
interest. 
 “Trademarks” means all of the following property now owned or hereafter acquired by the Company or any of its Subsidiaries or
in which the Company or any of its Subsidiaries now holds or hereafter acquires any interest: (a) all trademarks, trade names, corporate names, business names, trade styles, service marks, logos, other source or business identifiers, prints and
labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and any applications in connection therewith,
including, without limitation, registrations, recordings and applications in the Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof and
(b) reissues, extensions or renewals thereof. 
 “UCC” means the Uniform Commercial Code as the same may, from time to time, be in
effect in the State of Delaware; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Investor’s Lien on any Collateral is
governed by the Uniform Commercial Code as enacted and in effect in a jurisdiction other than the State of Delaware, the term “UCC” shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for
purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions. Unless otherwise defined herein, terms that are defined in the UCC and used herein shall
have the meanings given to them in the UCC. 
 [Remainder of page intentionally left blank] 
  

 33 

 IN WITNESS WHEREOF, the parties have
executed this Secured Note Purchase Agreement as of the date first written above. 
  

			
	COMPANY:
	
	ANESIVA, INC.
		
	By:	 	/s/ Michael L. Kranda
	Name:	 	Michael L. Kranda
	Title:	 	President and CEO
	
	400 Oyster Point, Suite 502
	South San Francisco, CA 94080

  

			
	INVESTOR:
	
	ARCION THERAPEUTICS, INC.
		
	By:	 	/s/ James N. Campbell, M.D.
	Name:	 	James N. Campbell, M.D.
	Title:	 	Chief Executive Officer
	
	2400 BOSTON STREET, SUITE 330,
	BALTIMORE, MD 21224

 EXHIBIT A 
 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). NO SALE, PLEDGE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE
REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT. 
 THIS NOTE IS SUBJECT TO THE TERMS AND CONDITIONS OF THE PURCHASE AGREEMENT (AS DEFINED BELOW). 
 NOTE 

  

							
	[                ]	  		  		  	[                ]

 For value received, Anesiva, Inc., a Delaware corporation (the “Company”),
promises to pay to the order of [            ] (together with its successors and assigns, the “Holder”), the principal sum of
[            ], together with interest accrued but unpaid thereon, upon the terms of this Note (the “Note”). 
 Interest shall accrue from the date hereof until maturity at a continuously compounding rate equal to ten percent (10%) per annum payable in cash;
provided, however, that, during the occurrence and continuance of an Event of Default (as defined in that certain Secured Note Purchase Agreement, dated as of May 18, 2009 (as amended, restated, supplemented or otherwise modified
from time to time, the “Purchase Agreement”), among the Company and the Holder), interest shall accrue at a continuously compounding rate equal to fourteen percent (14%) per annum. All computations of interest shall be made on
the basis of a year of 365 or 366 days, as the case may be, for the actual number of days (including the first day but excluding the last) occurring in the period for which such interest is payable. 
 Unless earlier paid pursuant to the terms hereof or the Purchase Agreement or accelerated in connection with an Event of Default, subject to the terms of
the Purchase Agreement, the outstanding principal and accrued but unpaid interest shall be immediately due and payable on October 20, 2009 (the “Maturity Date”). Company may prepay this Note at any time without penalty or
premium. 
 1. This Note is issued pursuant to the terms of the Purchase Agreement. The Holder is entitled to the benefit of, and is subject
to certain restrictions contained in, the Purchase Agreement and the other Related Documents. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Purchase Agreement. The indebtedness evidenced by this Note
is secured by certain collateral, as more particularly described in that certain Pledge, Security and Collateral Agent Agreement, dated as of May 18, 2009 (as may be further amended, restated, supplemented or modified from time to time, the
“Security Agreement”), among the Company, AlgoRx Pharmaceuticals, Inc. and the Collateral Agent and that certain Guaranty, dated as of January 20, 2009 (as may be further amended or modified from time to time, the
“Guaranty”) by and between AlgoRx Pharmaceuticals, Inc. and the Holder. 

 
Each holder of this Note will be deemed, by its acceptance hereof, to have agreed to the provisions and to have made the representations and warranties set
forth in Section 4 the Purchase Agreement. Subject to the terms of the Purchase Agreement, this Note is transferable by surrender hereof at the principal office of the Company, duly endorsed or accompanied by a written instrument of transfer
duly executed by the registered holder of this Note or by any other method permitted by the Purchase Agreement. 
 2. All payments hereunder
shall be applied in the order provided for in the Purchase Agreement. Whenever any payment hereunder shall be stated to be due, or whenever any return payment date or any other date specified hereunder would otherwise occur, on a day other than a
Business Day, then such payment shall be made, and such return payment date or other date shall occur, on the next succeeding Business Day, and such extension of time shall in such case be included in the computation of payment of interest
hereunder. 
 3. All payments in respect of this Note shall be in immediately available lawful money of the United States of America and
shall be sent so as to be received no later than 2 p.m. (Pacific time) on the date of payment, at the address specified in the Purchase Agreement, or at such other address as may be specified from time to time by such Holder in a written notice
delivered to the Company. All payments in respect of this Note shall be made unconditionally in full without any deduction, set off, counterclaim or other defense. If any scheduled payment date is not a Business Day, such payment shall be made on
the next succeeding Business Day. 
 4. The Company hereby waives demand, notice, presentment, protest and notice of dishonor. 
 5. (a) The terms of this Note shall be construed in accordance with the laws of the State of California, as applied to contracts entered into by
California residents within the State of California, which contracts are to be performed entirely within the State of California. The Company hereby (i) submits to the exclusive jurisdiction of the courts of the County of San Francisco, State
of California and the Federal courts of the United States sitting in the Northern District of the State of California for the purpose of any action or proceeding arising out of or relating to this Note, the Purchase Agreement and the Related
Documents; (ii) agrees that all claims in respect of any such action or proceeding may be heard and determined in such courts; (iii) irrevocably waives (to the extent permitted by applicable law) any objection that it now or hereafter may
have to the laying of venue of any such action or proceeding brought in any of the foregoing courts, and any objection on the ground that any such action or proceeding in any such court has been brought in an inconvenient forum; and (iv) agrees
that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner permitted by law. 
 (b) The parties agree that any dispute, controversy or claim (including any counterclaim) (each, a “Dispute”) arising out
of or relating to this Note, the Purchase Agreement or any Related Documents shall be finally resolved by confidential binding arbitration in San Francisco County, California as the sole and exclusive method of resolving such dispute, controversy or
claim. Any Dispute shall be settled by arbitration under the rules then in effect of JAMS/Endispute conducted by a single arbitrator reasonably acceptable to the parties. The arbitrator shall have no power to amend this Note, the Purchase Agreement
or any Related 

  

 2 

 
Documents. The arbitrator shall issue an award in writing (including an explanation of the grounds for such award) as promptly as practicable that shall be
final and binding on the parties. Judgment upon any award thus obtained may be entered in any court having jurisdiction thereof. No action at law or in equity based upon any claim arising out of or related to this Note, the Purchase Agreement or any
Related Documents shall be instituted in any court by any party except (a) an action to compel arbitration pursuant to this Section 5(b); or (b) an action to enforce an award obtained in an arbitration proceeding in accordance with
this Section 5(b). Pending the submission to arbitration and thereafter until the arbitrator publishes its award, each party shall, except in the event of termination, continue to perform all its obligations under this Note, the Purchase
Agreement and the Related Documents without prejudice to a final adjustment in accordance with the award. 
 6. Notwithstanding any provision
of this Note to the contrary, any payments hereunder deemed to be interest shall not exceed the maximum rate permitted by applicable law. To the extent that any interest otherwise paid or payable by the Company to the Holder shall have been finally
adjudicated to exceed the maximum amount permitted by applicable law, such interest shall be retroactively deemed to have been a required repayment of principal (and any such amount paid in excess of the outstanding principal amount shall be
promptly returned to the Company). 
 7. Any term of this Note and the other Securities may be amended and the observance of any term of this
Note and the other Securities may be waived (either generally or in a particular instance and either retroactively or prospectively), only in accordance with the terms of the Purchase Agreement. Any such amendment or waiver shall be effective only
for the specific instance and for the specific purpose for which given. 
 8. No remedy herein conferred upon the Holder is intended to be
exclusive of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to every right or other remedy now or hereafter existing at law or in equity or by statute or otherwise. 
 9. No course of dealing between the Company and the Holder or any delay on the part of the Holder in exercising any rights or remedies shall operate as a
waiver of any such right or remedy of the Holder. 
 10. This Note shall be binding on and inure to the benefit of and be enforceable by the
Company, the Holder and their respective successors and assigns. The Company may not assign, transfer, hypothecate or otherwise convey its rights, benefits, obligations or duties hereunder without the prior express written consent of the Majority
Investors. Any such purported assignment, transfer, hypothecation or other conveyance by the Company without the prior express written consent of the Majority Investors shall be void. 
 11. Whenever possible, each provision of this Note shall be interpreted in such manner as to be effective and valid under all applicable laws and
regulations. If, however, any provision of this Note shall be prohibited by or invalid under any such law or regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed modified to conform to the minimum requirements of such law or
regulation, or, if for any reason it is not deemed so modified, it shall be ineffective and invalid only to the extent of such prohibition or invalidity without affecting the remaining provisions of this Note, or the validity or effectiveness of
such provision in any other jurisdiction. 
  

 3 

 12. This Note is issued pursuant to the Purchase Agreement and in connection with the Security Agreement,
the Pledge Agreement and the other Related Documents. Material terms applicable to this Note are set forth in the Purchase Agreement, the Security Agreement, the Pledge Agreement and the other Related Documents. This Note shall be interpreted in a
manner to give full effect to its provisions and the provisions of the Purchase Agreement, the Security Agreement, the Pledge Agreement and the other Related Documents. 
 13. The Company agrees to pay on demand all costs and expenses of the Holder, and the reasonable fees and disbursements of its counsel (including the allocated costs of internal counsel), in connection with:
(i) any amendments, modifications or waivers of the terms hereof or of the Purchase Agreement or of any other Related Documents; (ii) the protection or preservation of the Holder’s rights under this Note, under the Purchase Agreement
or under any other Related Documents, whether by judicial proceeding or otherwise; (iii) enforcement or attempted enforcement of, and preservation of any rights under, this Note, the Purchase Agreement or any other Related Documents;
(iv) creating, maintaining and perfecting Liens in favor of the Collateral Agent, for the benefit of the Holder, including filing and recording fees and expenses, and (v) any out-of-court workout or other refinancing or restructuring or in
any bankruptcy case, including, without limitation, any and all losses, costs and expenses sustained by the Holder as a result of any failure by the Company to perform or observe its obligations contained herein or in the Purchase Agreement or in
any of the other Related Documents. 
 [Remainder of page intentionally left blank] 
  

 4 

 This Note has been issued in reliance upon the representations and warranties and covenants and
agreements of the Company and the Holder set forth in the Purchase Agreement. 
  

			
	ANESIVA, INC.
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

  

			
	Accepted and Agreed:
	
	[            ]
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

 [SIGNATURE PAGE TO SECURITY]

 EXHIBIT B 
 PLEDGE, SECURITY AND 
 COLLATERAL AGENT AGREEMENT 
 THIS PLEDGE, SECURITY AND COLLATERAL AGENT AGREEMENT (this “Agreement”), dated as of May 18, 2009, is made by and among Anesiva,
Inc., a Delaware corporation (“Anesiva”), and AlgoRx Pharmaceuticals, Inc., a Delaware corporation (together with Anesiva, each a “Grantor” and, collectively, the “Grantors”), the Secured
Parties (as defined below) and Arcion Therapeutics, Inc., as collateral agent for the Secured Parties (in such capacity, the “Collateral Agent”). 
 The Grantor, the Collateral Agent and the Secured Parties hereby agree as follows: 
 Section 1.
Definitions; Interpretation. 
 (a) All capitalized terms used in this Agreement and not otherwise defined
herein shall have the meanings assigned to them in the Purchase Agreement (as defined below). 
 (b) As used in this
Agreement, the following terms shall have the following meanings: 
 “Capital Stock” means (a) with respect to any
Person that is a corporation, any and all shares, interests or equivalents in capital stock (whether voting or nonvoting, and whether common or preferred) of such corporation and (b) with respect to any Person that is not a corporation, any and
all partnership, membership, limited liability company or other equity interests of such Person (including all economic, voting and other rights related thereto); and in each case, any and all warrants, rights or options to purchase any of the
foregoing. 
 “Collateral” has the meaning set forth in Section 2. 
 “Event of Default” has the meaning ascribed to it in the Purchase Agreement. 
 “Foreign Subsidiary” means any Subsidiary organized under the laws of any jurisdiction outside the United States of America. 

“Foreign Subsidiary Voting Stock” means the voting Capital Stock of any Foreign Subsidiary. 
 “Investment Property” means the collective reference to (a) all “investment property” as such term is defined in the UCC
(other than any Foreign Subsidiary Voting Stock excluded from the definition of “Pledged Stock” in this Section 1) and (b) whether or not constituting “investment property” as so defined, all Pledged Stock. 

“Issuers” means the collective reference to each issuer of any Investment Property. 

 “Majority Secured Parties” at any time means the Secured Parties holding at least sixty
percent (60%) of the aggregate principal amount of the Notes purchased pursuant to the Purchase Agreement and then outstanding. 
 “Permitted Lien” has the meaning ascribed to it in the Purchase Agreement. 
 “Pro Rata Share”
with respect to any Secured Party at any time, means the percentage equivalent to the outstanding principal amount plus accrued but unpaid returns of the Obligations owed to such Secured Party divided by the outstanding principal amount of all the
Obligations plus all accrued but unpaid returns owed to all Secured Parties. 
 “Pledged Stock” means the shares of Capital
Stock listed on Schedule 1, together with any other shares, stock certificates, options or rights of any nature whatsoever in respect of the Capital Stock of any Person that may be issued or granted to, or held by, any Grantor while this
Agreement is in effect; provided that in no event shall more than 65% of the total outstanding Foreign Subsidiary Voting Stock of any Foreign Subsidiary be required to be pledged hereunder. 
 “Proceeds” means all “proceeds” as such term is defined in the UCC and, in any event, including, without limitation, all
dividends or other income from the Investment Property, collections thereon or distributions or payments with respect thereto. 
 “Purchase Agreement” means that certain Secured Note Purchase Agreement of even date herewith by and among Anesiva and the Secured Parties party thereto, as it may be amended, restated, supplemented or otherwise modified
from time to time. 
 “Receivable” means any right to payment for goods sold, leased, licensed, assigned or otherwise
disposed of, or for services rendered, whether or not such right is evidenced by an Instrument or Chattel Paper and whether or not it has been earned by performance (including, without limitation, any Account and health-care insurance receivables).

 “Secured Party” means each Investor (as defined in the Purchase Agreement), and collectively the “Secured
Parties.” 
 “Notes” means, collectively, any secured promissory note issued from time to time by Anesiva pursuant
to the Purchase Agreement in favor of an Investor. 
 “UCC” means the Uniform Commercial Code as the same may, from time to
time, be in effect in the State of California; provided, however, in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of the security interest in any Collateral is governed
by the Uniform Commercial Code as in effect in a jurisdiction other than the State of California, the term “UCC” shall mean the Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions hereof relating
to such attachment, perfection or priority and for purposes of definitions related to such provisions. 
  

 2 

 (c) Where applicable and except as otherwise defined herein, terms used in this Agreement
shall have the meanings assigned to them in the UCC. 
 (d) In this Agreement, (i) the meaning of defined terms shall be
equally applicable to both the singular and plural forms of the terms defined; and (ii) the captions and headings are for convenience of reference only and shall not affect the construction of this Agreement. 
 Section 2. Security Interest. 
 (a) As security for the payment and performance of the Obligations, each Grantor hereby pledges, assigns, transfers, hypothecates and sets over to the Collateral Agent, for itself and on behalf of and for the ratable
benefit of the Secured Parties, and hereby grants to the Collateral Agent, a first priority security interest in, and right of setoff against, any and all of such Grantor’s right, title and interest in, to and under the following property,
wherever located and whether now existing or owned or hereafter acquired or arising (collectively, the “Collateral”): 
 (i) all accounts, accounts receivable, contract rights, rights to payment, chattel paper, rights to trade, letter-of-credit rights, documents, money and instruments and Investment Property, whether held directly or
through a securities intermediary, and other obligations of any kind owed to the Grantor, however evidenced; 
 (ii) all
deposits and deposit accounts with any bank, savings and loan association, credit union or like organization, and all funds and amounts therein, and whether or not held in trust, or in custody or safekeeping, or otherwise restricted or designated
for a particular purpose; 
 (iii) all inventory, including, without limitation, all materials, raw materials, parts,
components, work in progress, finished goods, merchandise, supplies and all other goods that are held for sale, lease or other disposition or furnished under contracts of service or consumed in such Grantor’s business, including, without
limitation, those held for display or demonstration or out on lease or consignment; 
 (iv) all equipment owned by such
Grantor, including, without limitation, all machinery, furniture, furnishings, fixtures, trade fixtures, tools, parts and supplies, appliances, computer and other electronic data processing equipment and other office equipment, computer programs and
related data processing software, and all additions, substitutions, replacements, parts, accessories and accessions to and for the foregoing; 
 (v) all general intangibles and other personal property of such Grantor, including, without limitation, (A) all tax and other refunds, rebates or credits of every kind and nature to which such Grantor is now or
hereafter may become entitled; (B) all intellectual property and all rights therein of any type or description, including, without limitation, all inventions and discoveries, patents and patent applications (and all inventions and improvements
described and claimed therein), copyrights and applications for copyright (together with the underlying works of authorship) whether or not registered, together with any renewals and extensions thereof, trademarks, service marks and trade names, and
applications for 

  

 3 

 
registration of such trademarks, service marks and trade names, trade secrets, trade dress, trade styles, , Internet domain names, logos, other source of
business identifiers, mask-works, mask-work registrations, mask-work applications, software, confidential and proprietary information, customer lists, other license rights, advertising materials, operating manuals, methods, processes, know-how,
algorithms, formulae, databases, quality control procedures, product, service and technical specifications, operating, production and quality control manuals, sales literature, drawings, specifications, blue prints, descriptions, inventions, name
plates and catalogs, and the entire good will of or associated with the businesses now or hereafter conducted by such Grantor connected with and symbolized by any of the aforementioned properties and assets, and all licenses relating to any of the
foregoing, all reissuance, renewals, continuations and continuations-in-part of the foregoing, all other rights derived from or associated with the foregoing, including the right to sue and recover for any and all past, present and future
infringement or misappropriations thereof, and all income and royalties with respect thereto; (C) all good will, choses in action and causes of action; (D) all interests in partnerships; and (E) all indemnity agreements, guaranties,
insurance policies, insurance claims and other contractual, equitable and legal rights of whatever kind or nature; 
 (vi) all
books, records and other written, electronic or other documentation in whatever form maintained by or for such Grantor in connection with the ownership of its assets or the conduct of its business or evidencing or containing information relating to
the Collateral; 
 (vii) all supporting obligations; and 
 (viii) all accessions, products and Proceeds at any time, including insurance proceeds, of any and all of the foregoing. 
 (b) Anything herein to the contrary notwithstanding, (i) the Grantors shall remain liable under any contracts, agreements and other
documents included in the Collateral, to the extent set forth therein, to perform all of their duties and obligations thereunder to the same extent as if this Agreement had not been executed; (ii) the exercise by the Collateral Agent or any of
the Secured Parties of any of the rights hereunder shall not release the Grantors from any of their duties or obligations under such contracts, agreements and other documents included in the Collateral; and (iii) none of the Secured Parties or
the Collateral Agent shall have any obligation or liability under any contracts, agreements and other documents included in the Collateral by reason of this Agreement, nor shall the Collateral Agent or any of the Secured Parties be obligated to
perform any of the obligations or duties of the Grantors thereunder or to take any action to collect or enforce any such contract, agreement or other document included in the Collateral hereunder. 
 (c) Notwithstanding the foregoing provisions of this Section 2, the grant of a security interest as provided herein shall not extend
to, and the term “Collateral” shall not include, any general intangibles or other assets of any Grantor (whether owned or held as licensee or lessee, or otherwise), to the extent that (i) such general intangibles or assets are not
assignable or capable of being encumbered as a matter of law or under the terms of the license, lease or other agreement applicable thereto (but solely to the extent that any such restriction shall be enforceable under applicable law), without the
consent of the licensor or lessor thereof or 

  

 4 

 
other applicable party thereto and (ii) such consent has not been obtained; provided, however, that the foregoing grant of security
interest shall extend to, and the term “Collateral” shall include, (A) any general intangible or asset that is an account receivable or a proceed of, or otherwise related to the enforcement or collection of, any account receivable, or
goods that are the subject of any account receivable; (B) any and all proceeds of any general intangibles or assets that are otherwise excluded to the extent that the assignment or encumbrance of such proceeds is not so restricted; and
(C) upon obtaining the consent of any such licensor, lessor or other applicable party’s consent with respect to any such otherwise excluded general intangibles or assets, such general intangibles and assets as well as any and all proceeds
thereof that might have theretofore have been excluded from such grant of a security interest and the term “Collateral.” 
 (d) Notwithstanding the foregoing provisions of this Section 2, the grant of a security interest as provided herein shall not extend to, and the term “Collateral” shall not include more than 65% of the total outstanding
Foreign Subsidiary Voting Stock of any Foreign Subsidiary. 
 (e) This Agreement shall create a continuing security interest
in the Collateral that shall remain in effect until terminated in accordance with Section 18 hereof. 
 Section 3. Pledge of
Pledged Collateral. 
 (a) Each Grantor hereby assigns and pledges to the Collateral Agent, its successors and
assigns, for the ratable benefit of the Secured Parties, a security interest in, all of such Grantor’s right, title and interest in, to and under (i) the Pledged Stock; (ii) subject to Section 9(d), all payments of dividends,
cash, instruments and other property from time to time received, receivable or otherwise distributed in respect of, in exchange for or upon conversion of, and all other Proceeds received in respect of the Pledged Stock; (iii) subject to
Section 9(d), all rights and privileges of such Grantor with respect to the securities and other property referred to in clauses (i) and (ii) above; and (iv) all Proceeds of any of the foregoing (the items in clauses
(i) through (iv) above being collectively referred to as the “Pledged Collateral”); 
 (b) Each
Grantor agrees to promptly deliver or cause to be delivered to the Collateral Agent any and all Pledged Stock. Upon delivery to the Collateral Agent, (i) any Pledged Stock shall be accompanied by stock powers duly executed in blank or other
instruments of transfer satisfactory to the Collateral Agent and by such other instruments and documents as the Collateral Agent may reasonably request and (ii) all other property comprising part of the Pledged Collateral shall be accompanied
by proper instruments of assignment duly executed by the applicable Grantor and such other instruments or documents as the Collateral Agent may reasonably request. Each delivery of Pledged Stock shall be accompanied by a schedule describing the
securities, which schedule shall be attached hereto as Schedule 1 and made a part hereof; provided that the failure to attach any such schedule hereto shall not affect the validity of such pledge of such Pledged Collateral. Each schedule so
delivered shall supplement any prior schedules so delivered. In the event that any Grantor shall deliver Pledged Stock representing more than 65% of the total outstanding Foreign Subsidiary Voting Stock of any Foreign Subsidiary, such Grantor shall
be deemed to have pledged and delivered 65% of the total outstanding Foreign Subsidiary Voting Stock of such Foreign Subsidiary. 
  

 5 

 Section 4. Collateral Agent and Indemnification. 
 (a) Each of the Secured Parties, by signing below or by its acceptance of the benefits of this Agreement, hereby appoints Arcion
Therapeutics, Inc. as “Collateral Agent.” Nothing in this Agreement shall restrict or prevent the Collateral Agent from being a Secured Party. In its capacity as a Secured Party, the Collateral Agent shall have the same rights and powers
under this Agreement, the Purchase Agreement and the Related Documents as any other Secured Party and may exercise the same as though it were not the Collateral Agent. In this regard, the term “Secured Party” shall, unless otherwise
expressly indicated, include the Collateral Agent in its individual capacity. The Collateral Agent shall receive no compensation but shall be entitled to reimbursement of expenses and indemnification as set forth herein. The Collateral Agent’s
duties and obligations shall commence as of the first day a Note is executed by Anesiva in favor of any Secured Party. Each Secured Party hereby authorizes the Collateral Agent to take such action as agent on its behalf and to exercise such powers
and perform such duties under this Agreement, the Purchase Agreement and the Related Documents as are delegated to the Collateral Agent by the terms hereof or thereof, together with such powers as are reasonably incidental thereto. The duties and
obligations of the Collateral Agent are strictly limited to those expressly provided for herein, and no implied covenants, functions, responsibilities, duties, obligations or liabilities shall be read into this Agreement or otherwise exist against
the Collateral Agent. Notwithstanding anything to the contrary contained herein, the Collateral Agent shall not be required to take any action that is contrary to this Agreement, the Purchase Agreement, the Related Documents or applicable law.

 (b) The Collateral Agent is hereby appointed as agent and attorney-in-fact and is authorized on behalf of each of the
Secured Parties and at the direction of the Majority Secured Parties to: (i) exercise or refrain from exercising any rights, remedies or powers of the Secured Parties under applicable law in respect of the Notes or all or any portion of any
Collateral; (ii) sell, release, surrender, realize upon or otherwise deal with, in any manner and in any order, all or any portion of any Collateral; (iii) make any demands or give any notices under or in connection with this Agreement,
the Purchase Agreement and the Related Documents; (iv) distribute payments to the Secured Parties of amounts paid to it by any Grantor or received by it in connection with the Collateral; (v) receive and hold on behalf of the Secured
Parties any instruments or other possessory Collateral; and (vi) engage, replace, instruct and remunerate on behalf of the Secured Parties consultants, experts, counsel and other persons to be engaged by the Collateral Agent or the Secured
Parties, including legal counsel for the Collateral Agent or the Secured Parties. As to the exercise of any of its powers and discharge of any of its duties, the Collateral Agent shall be entitled to obtain instructions of the Majority Secured
Parties, and shall be fully protected in acting or refraining from acting upon such instructions and such instructions shall be binding upon all Secured Parties. Except for actions expressly required of the Collateral Agent hereunder, the Collateral
Agent shall in all cases be fully justified in failing or refusing to act under this Agreement, the Purchase Agreement and the Related Documents unless it shall be indemnified to its satisfaction by the Secured Parties against any and all liability
and expense that may be incurred by reason of taking or continuing to take any such action, and the Collateral Agent shall not in any event be required to take any action that exposes the Collateral Agent to liability or that is contrary to this
Agreement, the Purchase Agreement, the Related Documents or applicable law. 
  

 6 

 (c) The Collateral Agent shall hold the Collateral for the ratable benefit of Secured
Parties in accordance with their Pro Rata Shares. Distribution of Collateral or any and all proceeds of any of the Collateral shall be made in accordance with Secured Parties respective Pro Rata Shares. 
 (d) Neither the Collateral Agent nor any of its directors, officers, employees or agents shall be responsible to any Secured Party for any
action taken or omitted to be taken by it or them hereunder or in connection herewith, except in the case of gross negligence or willful misconduct. The Collateral Agent may rely upon any notice, consent, certificate, telegram, facsimile, telex or
teletype message, statement or other instrument or writing believed by it to be genuine and signed or sent by the proper party or parties or by acting upon any representation or warranty made or deemed to be made hereunder or under any other Related
Document. The Collateral Agent shall use the level of care it uses with respect to its own property of a similar nature to assure the safe custody of the Collateral in its possession. Beyond the exercise of such level of care to assure the safe
custody of the Collateral in its possession as the Collateral Agent, and the accounting for any monies actually received by the Collateral Agent in such capacity, the Collateral Agent shall have no duty or liability to exercise or preserve any
rights, privileges and powers pertaining to the Collateral. 
 (e) The Secured Parties hereby agree to indemnify the
Collateral Agent, and any affiliates, directors, officers, employees, partners, members, agents, counsel and other advisors (collectively, the “Related Persons”) of the Collateral Agent ratably in accordance with their Pro Rata
Share, against and hold each of them harmless from any and all liabilities, obligations, losses, claims, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever, including the fees and
disbursements of counsel to the Collateral Agent (collectively, the “Liabilities”), that may be imposed on, incurred by or asserted against the Collateral Agent or any such Related Person to be indemnified, in any way relating to or
arising out of this Agreement, the Purchase Agreement or the Related Documents or any action taken or omitted by the Collateral Agent or other such Related Person to be indemnified in connection with any of the foregoing, unless such Liabilities
shall be caused by the willful misconduct or gross negligence of the Collateral Agent. 
 (f) The Collateral Agent may, in its
discretion, employ from time to time one or more agents or attorneys-in-fact (including any of the Collateral Agent’s affiliates) to perform any of the Collateral Agent’s duties under this Agreement, the Purchase Agreement and the Related
Documents. The Collateral Agent shall not be responsible for the negligence or misconduct of any agents or attorneys-in-fact selected by it with reasonable care. 
 (g) Subject to the appointment and acceptance of a successor Collateral Agent as provided below, the Collateral Agent may resign at any
time by giving five (5) Business Days’ written notice thereof to the Secured Parties and the Grantors. Upon any such resignation, the Majority Secured Parties shall have the right to appoint a successor Collateral Agent from among the
Secured Parties, and the Secured Parties shall use their best efforts so to appoint a successor Collateral Agent. The Grantors shall promptly execute all documents and instruments necessary to convey all rights and interests under this Agreement and
related documents and instruments to any successor Collateral Agent. If no successor Collateral Agent shall have been so appointed by the Majority Secured Parties, and shall have accepted 

  

 7 

 
such appointment, prior to the effective date of the retiring Collateral Agent’s resignation, the retiring Collateral Agent may, on behalf of the
Secured Parties, appoint a successor Collateral Agent from among the Secured Parties. Upon the effectiveness of the acceptance of any appointment as Collateral Agent hereunder by a successor Collateral Agent, such successor Collateral Agent shall
thereupon succeed to and become vested with all the rights, powers, privileges, duties and obligations of the retiring Collateral Agent, and the retiring Collateral Agent shall be discharged from its duties and obligations under this Agreement, the
Purchase Agreement and the Related Documents. After any retiring Collateral Agent’s resignation hereunder as Collateral Agent, the provisions of this Section 4 shall inure to its benefit as to any actions taken or omitted to be taken by it
while it was Collateral Agent under this Agreement, the Purchase Agreement and the Related Documents. 
 Section 5. Financing
Statements; Further Assurances. 
 (a) Pursuant to any applicable law, each Grantor authorizes the Collateral Agent to
file or record financing statements and other filing or recording documents or instruments with respect to the Collateral without the signature of such Grantor in such form and in such offices as the Collateral Agent determines appropriate to
perfect the security interests granted hereby. Each Grantor authorizes the Collateral Agent to use the collateral description “all personal property” or “all assets” in any such financing statements. Each Grantor hereby ratifies
and authorizes the filing by the Collateral Agent of any financing statement with respect to the Collateral made prior to the date hereof. 
 (b) Upon request to a Grantor by the Collateral Agent, at any time following the execution of this Agreement, and at any time and from time to time thereafter, each Grantor shall promptly execute, acknowledge and
deliver, or cause the execution acknowledgment and delivery of, and, as applicable, thereafter register, file or record, or cause to be registered, filed or recorded, all financing statements, assignments, continuation financing statements,
termination statements, account control agreements, intellectual property security agreements and other documents and instruments, in form reasonably satisfactory to the Collateral Agent, and take all other action, as the Collateral Agent may
reasonably request, including, without limitation, the provision of assistance in the preparation of any of the aforementioned documents and instruments and the filing of intellectual property security agreements with the United States Patent and
Trademark Office and the United States Copyright Office, to perfect and continue perfected, maintain the priority of or provide notice of the security interest of the Collateral Agent in the Collateral subject to no Liens other than Permitted Liens
and to accomplish the purposes of this Agreement. Without limiting the generality of the foregoing, each Grantor will: (a) (i) execute (if necessary) and file such financing or continuation statements, or amendments thereto,
(ii) execute and deliver, and cause to be executed and delivered, agreements establishing that the Collateral Agent has control of deposit accounts and Investment Property of such Grantor and (iii) deliver such instruments or notices, in
each case, as may be necessary or desirable, or as Collateral Agent may request, in order to perfect and preserve the security interests granted or purported to be granted hereby; (b) furnish to the Collateral Agent from time to time statements
and schedules further identifying and describing the Collateral and such other reports in connection with the Collateral as the Collateral Agent may reasonably request, all in reasonable detail; (c) at any reasonable time, upon request by the
Collateral Agent, exhibit the Collateral to and allow inspection of the 

  

 8 

 
Collateral by the Collateral Agent, or persons designated by the Collateral Agent; (d) at Collateral Agent’s request, appear in and defend any
action or proceeding that may affect such Grantor’s title to or the Collateral Agent’s security interest in all or any part of the Collateral; and (e) use commercially reasonable efforts to obtain any necessary consents of third
parties to the creation and perfection of a security interest in favor of the Collateral Agent with respect to any Collateral. Upon the exercise by the Collateral Agent or the Secured Parties of any power, right, privilege or remedy pursuant to this
Security Agreement, the Purchase Agreement or the Related Documents which requires any consent, approval, registration, qualification or authorization of any governmental authority, Grantor and each of its Subsidiaries shall execute and deliver all
applications, certifications, instruments and other documents and papers that the Collateral Agent or the Secured Parties may be so required to obtain. 
 Section 6. Representations and Warranties. To induce the Collateral Agent and the Secured Parties to enter into the Purchase Agreement and to induce the Investors to make their respective extensions of
credit to Anesiva thereunder, each Grantor hereby, jointly and severally, represents and warrants to the Collateral Agent and each other Secured Party that: 
 (a) The Grantor is a corporation duly organized, validly existing and in good standing under the law of the jurisdiction of its
incorporation and has all requisite power and authority to execute, deliver and perform its obligations under this Agreement. 
 (b) All corporate action on the part of the Grantors, their officers, directors and stockholders necessary for the authorization, execution and delivery of this Agreement, the Purchase Agreement and the Related Documents, the performance of
all obligations of the Grantors hereunder and thereunder and the authorization, issuance and delivery of the Notes has been taken or will be taken prior to the Initial Closing, and this Agreement, the Purchase Agreement and the Related Documents,
when executed and delivered by the Grantors, shall constitute valid and legally binding obligations of the Grantors, enforceable against the Grantors in accordance with their terms except as limited by applicable bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance and other laws of general application affecting enforcement of creditors’ rights generally and as limited by laws relating to the availability of specific performance, injunctive relief or other
equitable remedies. 
 (c) No consent, approval, order or authorization of, or registration, qualification, designation,
declaration or filing with, any foreign, federal, state or local governmental authority or any third party on the part of the Grantors is required in connection with the consummation of the transactions (including the granting of the security
interest in the Collateral, the perfection of such security interest (to the extent such security interest can be perfected by filing under the UCC, the granting of control (to the extent required under section 7(h) hereof) or by filing appropriate
documents with the United States Patent and Trademark Office or the United States Copyright Office) and the exercise of the rights and remedies thereunder) contemplated by the Purchase Agreement and the Related Documents, except for (i) filings
pursuant to applicable state securities laws and Regulation D of the Securities Act of 1933, as amended, which filings will be effected within the time prescribed by law and (ii) the filing or recording of UCC financing statements, the filing
of appropriate documentation with the United States Patent and Trademark Office and the United States Copyright Office, obtaining control to perfect the Liens created by this Agreement (to the extent required under Section 7(h) hereof), such
actions as may be required by applicable foreign Laws affecting the pledge of the Pledged Equity of Foreign Subsidiaries and foreign Copyrights, Trademarks and Patents and consents, authorizations, filings or other actions which have been obtained
or made. 
  

 9 

 (d) Each Grantor’s chief executive offices and principal places of business are
located at the addresses set forth in Schedule 1; all other locations where each of the Grantors conduct business or the Collateral is kept are set forth in Schedule 3; and all trade names and fictitious names under which each of the
Grantors at any time in the past have conducted or presently conduct their business operations are set forth in Schedule 1. 
 (e) Each of the Grantor’s U.S. and foreign patents and patent applications, registered copyrights, applications for copyright, trademarks, service marks and trade names (whether registered or unregistered), and applications for
registration of such trademarks, service marks and trade names, are set forth in Schedule 2. 
 (f) (i) This
Agreement creates a first priority security interest in favor of the Collateral Agent, for the benefit of the Secured Parties, that is enforceable against the Collateral in which the Grantors now have rights and will create a security interest that
is enforceable against the Collateral in which the Grantors hereafter acquire rights at the time any Grantor acquires any such rights and (ii) the Secured Parties have a perfected and first priority security interest in the Collateral in which
the Grantors now have rights, and will have a perfected and first priority security interest in the Collateral in which the Grantors hereafter acquire rights at the time any Grantor acquires any such rights, in each case securing the payment and
performance of the Obligations, free and clear of all Liens except in each case for Permitted Liens. 
 (g) The names and
addresses of all financial institutions at which any Grantor maintains its deposit accounts, and the account numbers and account names of such deposit accounts, are set forth in Schedule 1. 
 (h) All securities accounts of the Grantors and other Investment Property of the Grantors are set forth in Schedule 1. No account
control agreements exist with respect to any Investment Property other than any account control agreements in favor of the Secured Parties. 
 (i) The Grantors have the right and power to pledge, sell, assign and transfer the Collateral, and the Grantors are the sole and complete legal and beneficial owners of the Collateral, free from any Lien other than
Permitted Liens. There exists no adverse claim with respect to the Pledged Stock of any Grantor. 
 (j) (i) The shares of
Pledged Stock pledged by any Grantor hereunder constitute all the issued and outstanding shares of all classes of the Capital Stock of each Issuer owned by such Grantor or, in the case of a Foreign Subsidiary Voting Stock, if less, 65% of the
outstanding Foreign Subsidiary Voting Stock of each relevant Issuer. 
 (ii) All the shares of the Pledged Stock have been
duly and validly issued and are fully paid and nonassessable and is not subject to the preemptive rights of any Person. 
  

 10 

 (iii) Schedule 1 correctly sets forth the percentage of the issued and outstanding
shares of each class of Capital Stock of the Issuer thereof represented by such Pledged Stock. 
 (iv) Such Grantor is the
record and beneficial owner of, and has good and marketable title to, the Investment Property pledged by it hereunder, free of any and all Liens or options in favor of, or claims of, any other Person. 
 (v) Except for restrictions and limitations imposed by the Purchase Agreement, the Related Documents or securities laws generally, the
Pledged Stock is and will continue to be freely transferable and assignable, and none of the Pledged Collateral is or will be subject to any option, right of first refusal, shareholders agreement, charter or by-law provisions or contractual
restriction of any nature that might prohibit, impair, delay or otherwise affect the pledge of such Pledged Collateral hereunder, the sale or disposition thereof pursuant hereto or the exercise by the Collateral Agent of rights and remedies
hereunder. 
 (vi) By virtue of the execution and delivery by the Grantors of this Agreement, when any Pledged Stock is
delivered to the Collateral Agent in accordance with this Agreement, the Collateral Agent will obtain a legal, valid and perfected first priority lien upon and security interest in such Pledged Stock as security for the payment and performance of
the Obligations. 
 (vii) The pledge effected hereby is effective to vest in the Collateral Agent, for the benefit of the
Secured Parties, the rights of the Collateral Agent in the Pledged Collateral as set forth herein. 
 (k) As of the time any
Receivable owned by a Grantor becomes subject to the security interest provided for hereby, and at all times thereafter, such Grantor shall be deemed to have represented and warranted as to each and all of such Receivables that: 
 (i) all representations and warranties of such Grantor set forth in this Agreement are true and correct in all material respects with
respect to each such Receivable; 
 (ii) each Receivable represents a bona fide transaction completed in accordance with the
terms and provisions contained in the invoices and other documents evidencing the same in all material respects, and all such invoices and other documents relating thereto are genuine and in all material respects what they purport to be; 

(iii) each Receivable is valid and subsisting; that no amount payable to such Grantor under or in connection with any Receivable is
evidenced by any Instrument or Chattel Paper which has not been delivered to the Collateral Agent to the extent required by Section 7(h); 
 (iv) the amount of such Receivable represented as owing is not disputed and is not subject to any set-offs, credits, deductions or countercharges other than those arising in the ordinary course of business; and

  

 11 

 (v) the goods giving rise to Receivables are not subject to any Lien, except in favor of
the Collateral Agent and the Secured Parties and except as permitted by the Purchase Agreement and the Related Documents. 
 (l) As of the Closing Date, no Obligor has any Commercial Tort Claims. 
 (m) With respect to any equipment and/or
inventory of a Grantor, each such Grantor has exclusive possession and control (including through rented space in a warehouse) of such equipment and inventory of such Grantor except for (i) equipment leased by such Grantor as a lessee or
(ii) equipment or inventory in transit with common carriers. No inventory of a Grantor is held by a Person other than a Grantor pursuant to consignment, sale or return, sale on approval or similar arrangement. 
 Section 7. Covenants. So long as any of the Obligations remain unsatisfied, each Grantor agrees that: 
 (a) Such Grantor shall appear in and defend any action, suit or proceeding that may affect to a material extent its title to, or right or
interest in, or Collateral Agent’s right or interest in, the Collateral, and shall do and perform all reasonable acts that may be necessary and appropriate to maintain, preserve and protect in all material respects the Collateral. 

(b) Such Grantor shall comply in all material respects with all laws, regulations and ordinances, and all policies of insurance,
relating in a material way to the possession, operation, maintenance and control of the Collateral. 
 (c) Such Grantor shall
give prompt written notice to the Collateral Agent (and in any event not later than ten (10) days prior to any change described below in this subsection) of: (i) any change in the location of a Grantor’s chief executive office or
principal place of business; (ii) any change in the locations set forth in Schedule 1 or Schedule 3; (iii) any change in its name; (iv) any changes in, additions to or other modifications of its trade names and
trade styles set forth in Schedule 1 or Schedule 2; and (v) any changes in its identity or structure, including its jurisdiction of organization, in any manner that might make any financing statement filed hereunder
incorrect or misleading. 
 (d) Such Grantor shall carry and maintain in full force and effect, at its own expense and with
financially sound and reputable insurance companies, insurance with respect to the Collateral in such amounts, with such deductibles and covering such risks as is customarily carried by companies engaged in the same or similar businesses and owning
similar properties in the localities where such Grantor operates. 
 (e) Such Grantor shall not surrender or lose possession
of (other than to the Collateral Agent), sell, lease, rent or otherwise dispose of or transfer any of the Collateral or any right or interest therein, except in the ordinary course of business; provided that no such disposition or transfer of
Collateral consisting of Investment Property or instruments shall be permitted while any Event of Default exists. 
  

 12 

 (f) Such Grantor shall keep the Collateral free of all Liens except Permitted Liens.

 (g) Such Grantor shall maintain and preserve its corporate existence, its rights to transact business and all other rights,
franchises and privileges necessary or reasonably desirable in the normal course of its business and operations and the ownership of the Collateral, except in connection with any transactions expressly permitted by the Purchase Agreement or the
Related Documents. 
 (h) Such Grantor shall (i) immediately deliver to the Collateral Agent appropriately endorsed or
accompanied by appropriate instruments of transfer or assignment, all documents and instruments, all certificated securities with respect to any Investment Property, all letters of credit and all accounts and other rights to payment at any time
evidenced by promissory notes, trade acceptances or other instruments; (ii) cause any securities intermediaries to show on their books that the Collateral Agent is the entitlement holder with respect to any Investment Property, and/or upon the
request of the Collateral Agent obtain account control agreements in favor of the Collateral Agent from such securities intermediaries, in form and substance satisfactory to the Collateral Agent with respect to any Investment Property;
(iii) mark all documents and chattel paper with such legends as the Collateral Agent shall reasonably specify; and (iv) obtain consents from any letter of credit issuers with respect to the assignment to the Collateral Agent of any letter
of credit proceeds. 
 (i) If and when such Grantor shall obtain rights to any material new patents, trademarks, service
marks, trade names, mask works or copyrights, or otherwise acquire or become entitled to the benefit of, or apply for registration of, any of the foregoing, such Grantor (i) shall promptly notify the Collateral Agent thereof and
(ii) hereby authorizes the Collateral Agent to modify, amend or supplement Schedule 2 and from time to time to include any of the foregoing and make all necessary or appropriate filings with respect to the perfection of any security
interest therein granted pursuant to this Agreement. 
 (j) The Grantor shall promptly notify the Collateral Agent of the
establishment of any deposit account or other bank account. 
 (k) (i) If such Grantor shall become entitled to receive or
shall receive any certificate (including, without limitation, any certificate representing a dividend or a distribution in connection with any reclassification, increase or reduction of capital or any certificate issued in connection with any
reorganization), option or rights in respect of the Capital Stock of any Issuer, whether in addition to, in substitution of, as a conversion of, or in exchange for, any shares of the Pledged Stock, or otherwise in respect thereof, such Grantor shall
accept the same as the agent of the Collateral Agent and the Secured Parties, hold the same in trust for the Collateral Agent and the Secured Parties and deliver the same forthwith to the Collateral Agent in the exact form received, duly indorsed by
such Grantor to the Collateral Agent, if required, together with an undated stock power covering such certificate duly executed in blank by such Grantor and with, if the Collateral Agent so requests, signature guaranteed, to be held by the
Collateral Agent, subject to the terms hereof, as additional collateral security for the Obligations; provided that, notwithstanding anything in the foregoing to the contrary, no Grantor shall be required to deliver certificates
evidencing more than 65% of the total outstanding 

  

 13 

 
Foreign Subsidiary Voting Stock. Any sums paid upon or in respect of the Investment Property upon the liquidation or dissolution of any Issuer shall be paid
over to the Collateral Agent to be held by it hereunder as additional collateral security for the Obligations, and in case any distribution of capital shall be made on or in respect of the Investment Property, or any property shall be distributed
upon or with respect to the Investment Property pursuant to the recapitalization or reclassification of the capital of any Issuer or pursuant to the reorganization thereof, the property so distributed shall, unless otherwise subject to a perfected
security interest in favor of the Collateral Agent, be delivered to the Collateral Agent to be held by it hereunder as additional collateral security for the Obligations. If any sums of money or property so paid or distributed in respect of the
Investment Property shall be received by such Grantor, such Grantor shall, until such money or property is paid or delivered to the Collateral Agent, hold such money or property in trust for the Secured Parties, segregated from other funds of such
Grantor, as additional collateral security for the Obligations. 
 (ii) Without the prior written consent of the Collateral
Agent, such Grantor will not (i) vote to enable, or take any other action to permit, any Issuer to issue any stock or other equity securities of any nature or to issue any other securities convertible into or granting the right to purchase or
exchange for any stock or other equity securities of any nature of any Issuer, unless such securities are delivered to the Collateral Agent, concurrently with the issuance thereof, to be held by the Collateral Agent as Collateral, (ii) sell,
assign, transfer, exchange or otherwise dispose of, or grant any option with respect to, the Investment Property or Proceeds thereof (except pursuant to a transaction expressly permitted by the Purchase Agreement), (iii) create, incur or permit
to exist any Lien or option in favor of, or any claim of any Person with respect to, any of the Investment Property or Proceeds thereof, or any interest therein, except for Permitted Liens or (iv) enter into any agreement or undertaking
restricting the right or ability of such Grantor or the Collateral Agent to sell, assign or transfer any of the Pledged Collateral. 
 (iii) In the case of each Grantor which is an Issuer, such Issuer agrees that (i) it will be bound by the terms of this Agreement relating to the Pledged Stock issued by it and will comply with such terms insofar as such terms are
applicable to it, (ii) it will notify the Collateral Agent promptly in writing of the occurrence of any of the events described in Section 7(k)(i) with respect to the Pledged Stock issued by it and (iii) the terms of Sections 9(d) and
9(e) shall apply to it, mutatis mutandis, with respect to all actions that may be required of it pursuant to Sections 9(d) or 9(e) with respect to the Pledged Stock issued by it. 
 (iv) Each interest in any limited liability company or partnership controlled by any Grantor and pledged hereunder shall be represented by
a certificate, shall be a “security” within the meaning of Article 8 of the UCC and shall be governed by the UCC. 
 (l) Such Grantor shall pay promptly when due all property and other taxes, assessments and governmental charges or levies imposed upon, and all claims (including claims for labor, services, materials and supplies) against, the Collateral
except to the extent the validity thereof is being contested in good faith; provided that such Grantor shall in any event pay such taxes, assessments, charges, levies or claims not later than five days prior to the date of any proposed sale under
any judgment, writ or warrant of attachment entered or filed against such Grantor or any of the Collateral as a result of the failure to make such payment. 
  

 14 

 (m) Such Grantor shall permit representatives of the Collateral Agent at any time during
normal business hours to inspect and make abstracts from records of the Collateral, and each Grantor agrees to render to the Collateral Agent, at such Grantor’s cost and expense, such clerical and other assistance as may be reasonably requested
with regard thereto. 
 Section 8. Authorization; Collateral Agent Appointed Attorney-in-Fact. The Collateral Agent shall have
the right to, in the name of any Grantor, or in the name of the Secured Parties or the Collateral Agent or otherwise, and each Grantor hereby constitutes and appoints the Collateral Agent (and any of the Collateral Agent’s officers, employees
or agents designated by the Collateral Agent) as such Grantor’s true and lawful attorney-in-fact, with full power and authority to in the place and stead of such Grantor, from time to time in the Collateral Agent’s discretion to take any
action and to execute any instrument that the Collateral may deem necessary or advisable to maintain, realize upon and preserve the Collateral and the Collateral Agent’s security interest, on behalf of the Secured Parties, therein and to
accomplish the purposes of this Agreement, including, without limitation: 
 (a) upon the occurrence and during the
continuance of an Event of Default, to obtain and adjust any insurance required to be maintained by such Grantor; 
 (b) upon
the occurrence and during the continuance of an Event of Default, to ask for, demand, collect, sue for, recover, compound, receive and give acquittance and receipts for moneys due and to become due under or in respect of any of the Collateral;

 (c) upon the occurrence and during the continuance of an Event of Default, to receive, endorse and collect any drafts or
other instruments, chattel paper and other documents in connection with clauses (a) and (b) above; 
 (d) upon the
occurrence and during the continuance of an Event of Default, to file any claims or take any action or institute any proceedings that the Collateral Agent may deem necessary or desirable for the collection of any of the Collateral or otherwise to
enforce or protect the rights of a Secured Party with respect to any of the Collateral; 
 (e) to pay or discharge liens
(other than liens permitted under this Agreement or the Purchase Agreement) levied or placed upon or threatened against the Collateral, the legality or validity thereof and the amounts necessary to discharge the same to be determined by the
Collateral Agent in its sole discretion, any such payments made by the Collateral Agent to become obligations of such Grantor to the Collateral Agent, due and payable immediately without demand; 
 (f) upon the occurrence and during the continuance of an Event of Default, to sign and endorse any invoices, freight or express bills,
bills of lading, storage or warehouse receipts, drafts against debtors, assignments, verifications and notices in connection with accounts and other documents relating to the Collateral; and 
  

 15 

 (g) upon the occurrence and during the continuance of an Event of Default, generally to
sell, transfer, pledge, make any agreement with respect to or otherwise deal with any of the Collateral as fully and completely as though the Collateral Agent were the absolute owner thereof for all purposes, and to do, at the Collateral
Agent’s option and the Grantors’ expense, at any time or from time to time, all acts and things that the Collateral Agent deems necessary to protect, preserve or realize upon the Collateral and the Collateral Agent’s security interest
therein in order to effect the intent of this Agreement, all as fully and effectively as such Grantor might do. 
 The foregoing power of
attorney is coupled with an interest and irrevocable so long as the Obligations have not been paid in full in cash and performed in full. Each Grantor hereby ratifies, to the extent permitted by law, all that the Collateral Agent shall lawfully and
in good faith do or cause to be done by virtue of and in compliance with this Section 8. 
 Section 9. Remedies.

 (a) In addition to all other rights and remedies granted to it in this Agreement, the Purchase Agreement or any of the
Related Documents, each Secured Party, through the Collateral Agent, shall be entitled to all rights and remedies of a secured party under the UCC (whether or not the UCC applies to the affected Collateral) and other applicable laws. Without
limiting the generality of the foregoing, the Collateral Agent, at its sole discretion, may (i) require each Grantor to, and each Grantor hereby agrees that it will at its expense and upon request of the Collateral Agent forthwith, assemble all
or part of the Collateral as directed by the Collateral Agent and make it available to the Collateral Agent at a place to be designated by the Collateral Agent that is reasonably convenient to both parties, (ii) enter onto the property where
any Collateral is located and take possession thereof with or without judicial process, (iii) prior to the disposition of the Collateral, store, process, repair or recondition the Collateral or otherwise prepare the Collateral for disposition
in any manner to the extent the Collateral Agent deems appropriate, (iv) consistent with commercial reasonableness, take possession of any Grantor’s premises or place custodians in exclusive control thereof, remain on such premises and use
the same and any of such Grantor’s equipment for the purpose of completing any work in process, taking any actions described in the preceding clause (iii) and collecting any obligation and (v) sell, resell, lease, use, assign,
license, sublicense, transfer or otherwise dispose of any or all of the Collateral in its then condition or following any commercially reasonable preparation or processing (utilizing in connection therewith any of the Grantors’ assets, without
charge or liability to the Secured Parties therefor) at public or private sale, by one or more contracts, in one or more parcels, at the same or different times, for cash or credit, or for future delivery without assumption of any credit risk;
provided, however, that the Grantors shall be credited with the net proceeds of sale only when such proceeds are finally collected by the Collateral Agent. The Collateral Agent shall have the right upon any such public sale, and, to
the extent permitted by law, upon any such private sale, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption, which right or equity of redemption the Grantors hereby release, to the extent permitted
by law. Each of the Secured Parties hereby authorizes the Collateral Agent to credit bid all or any part of the Obligations owed to such Secured Party. The Collateral Agent shall make such bids in accordance with each Secured Party’s Pro Rata
Share and shall hold any Collateral so acquired in trust on behalf of the Secured Parties in accordance with their respective Pro Rata Shares. The Grantors hereby agree that the sending of notice by 

  

 16 

 
ordinary mail, postage prepaid, to the address of the Grantors set forth herein, of the place and time of any public sale or of the time after which any
private sale or other intended disposition is to be made, shall be deemed reasonable notice thereof if such notice is sent ten (10) Business Days prior to the date of such sale or other disposition or the date on or after which such sale or
other disposition may occur, provided that the Collateral Agent may provide the Grantors shorter notice or no notice, to the extent permitted by the UCC or other applicable law. 
 (b) Solely for the purpose of enabling the Collateral Agent to exercise its rights and remedies under this Agreement, effective upon the
occurrence and during the continuance of an Event of Default, the Grantors hereby grant the Collateral Agent an irrevocable, non-exclusive and assignable license (exercisable without payment or royalty or other compensation to the Grantors) to use,
license or sublicense any of the Collateral. 
 (c) The cash proceeds actually received from the sale or other disposition or
collection of the Collateral and any other amounts received in respect of the Collateral or the application of which is not otherwise provided for herein, shall be applied first, to the payment of the reasonable costs and expenses of the
Collateral Agent (including the reasonable costs and expenses of legal counsel) in exercising or enforcing its rights hereunder and in collecting or attempting to collect any of the Collateral; and second, to the payment of the Obligations.
Any surplus thereof that exists after payment and performance in full of the Obligations shall be promptly paid over to the Grantors or otherwise disposed of in accordance with the UCC or other applicable law. The Grantors shall remain liable to the
Collateral Agent and the Secured Parties for any deficiency that exists after any sale or other disposition or collection of the Collateral. 
 (d) (i) Unless an Event of Default shall have occurred and be continuing and the Collateral Agent shall have given notice to the relevant Grantor of the Collateral Agent’s intent to exercise its corresponding
rights pursuant to Section 9(d)(ii), each Grantor shall be permitted to receive all cash dividends paid in respect of the Pledged Stock paid in the normal course of business of the relevant Issuer and consistent with past practice, to the
extent permitted in the Purchase Agreement, and to exercise all voting and corporate rights with respect to the Pledged Collateral; provided, however, that no vote shall be cast or corporate right exercised or other action taken which,
in the Collateral Agent’s reasonable judgment, would impair the Collateral or which would be inconsistent with or result in any violation of any provision of the Purchase Agreement, this Agreement or any Related Document. 
 (ii) If an Event of Default shall occur and be continuing and the Collateral Agent shall give notice of its intent to exercise such rights
to the relevant Grantor or Grantors, (i) the Collateral Agent shall have the right to receive any and all cash dividends, payments or other Proceeds paid in respect of the Pledged Collateral and make application thereof to the Obligations in
the order set forth in Section 9(c) and (ii) any or all of the Pledged Collateral shall be registered in the name of the Collateral Agent or its nominee, and the Collateral Agent or its nominee may thereafter exercise (x) all voting,
corporate and other rights pertaining to such Pledged Collateral at any meeting of stockholders of the relevant Issuer or Issuers or otherwise and (y) any and all rights of conversion, exchange and subscription and any other rights, privileges
or options pertaining to such Pledged Collateral as if it were the absolute owner thereof (including, without limitation, the right to exchange at its discretion any and all of 

  

 17 

 
the Pledged Collateral upon the merger, consolidation, reorganization, recapitalization or other fundamental change in the corporate structure of any Issuer,
or upon the exercise by any Grantor or the Collateral Agent of any right, privilege or option pertaining to such Pledged Collateral, and in connection therewith, the right to deposit and deliver any and all of the Pledged Collateral with any
committee, depositary, transfer agent, registrar or other designated agency upon such terms and conditions as the Agent may determine), all without liability except to account for property actually received by it, but the Collateral Agent shall have
no duty to any Grantor to exercise any such right, privilege or option and shall not be responsible for any failure to do so or delay in so doing. 
 (iii) Each Grantor hereby authorizes and instructs each Issuer of any Pledged Collateral pledged by such Grantor hereunder to (i) comply with any instruction received by it from the Collateral Agent in writing
that (x) states that an Event of Default has occurred and is continuing and (y) is otherwise in accordance with the terms of this Agreement, without any other or further instructions from such Grantor, and each Grantor agrees that each
Issuer shall be fully protected in so complying and (ii) unless otherwise expressly permitted hereby, pay any dividends or other payments with respect to the Pledged Collateral directly to the Collateral Agent. 
 (e) (i) If the Collateral Agent shall determine to exercise its right to sell any or all of the Pledged Stock pursuant to
Section 9(a), and if in the opinion of the Collateral Agent it is necessary or advisable to have the Pledged Stock, or that portion thereof to be sold, registered under the provisions of the Securities Act of 1933, as amended, the relevant
Grantor will cause the Issuer thereof to (i) execute and deliver, and cause the directors and officers of such Issuer to execute and deliver, all such instruments and documents, and do or cause to be done all such other acts as may be, in the
opinion of the Collateral Agent, necessary or advisable to register the Pledged Stock, or that portion thereof to be sold, under the provisions of the Securities Act of 1933, as amended, (ii) use its best efforts to cause the registration
statement relating thereto to become effective and to remain effective for a period of one year from the date of the first public offering of the Pledged Stock, or that portion thereof to be sold, and (iii) make all amendments thereto and/or to
the related prospectus which, in the opinion of the Collateral Agent, are necessary or advisable, all in conformity with the requirements of the Securities Act of 1933, as amended, and the rules and regulations of the Securities and Exchange
Commission applicable thereto. Each Grantor agrees to cause such Issuer to comply with the provisions of the securities or “Blue Sky” laws of any and all jurisdictions that the Collateral Agent shall designate and to make available to its
security holders, as soon as practicable, an earnings statement (which need not be audited) which will satisfy the provisions of Section 11(a) of the Securities Act of 1933, as amended. 
 (ii) Each Grantor recognizes that the Collateral Agent may be unable to effect a public sale of any or all the Pledged Stock, by reason of
certain prohibitions contained in the Securities Act of 1933, as amended, and applicable state securities laws or otherwise, and may be compelled to resort to one or more private sales thereof to a restricted group of purchasers that will be obliged
to agree, among other things, to acquire such securities for their own account for investment and not with a view to the distribution or resale thereof. Each Grantor acknowledges and agrees that any such private sale may result in prices and other
terms less favorable than if such sale were a public sale and, notwithstanding such 

  

 18 

 
circumstances, agrees that any such private sale shall be deemed to have been made in a commercially reasonable manner. The Collateral Agent shall be under
no obligation to delay a sale of any of the Pledged Stock for the period of time necessary to permit the Issuer thereof to register such securities for public sale under the Securities Act of 1933, as amended, or under applicable state securities
Laws, even if such Issuer would agree to do so. 
 (iii) Each Grantor agrees to use its best efforts to do or cause to be done
all such other acts as may be necessary to make such sale or sales of all or any portion of the Pledged Stock pursuant to this Section 9(e) valid and binding and in compliance with any and all other applicable laws. Each Grantor further agrees
that a breach of any of the covenants contained in this Section 9(e) will cause irreparable injury to the Collateral Agent and the Secured Parties, that the Collateral Agent and the Secured Parties have no adequate remedy at law in respect of
such breach and, as a consequence, that each and every covenant contained in this Section 9(e) shall be specifically enforceable against such Grantor, and such Grantor hereby waives and agrees not to assert any defenses against an action for
specific performance of such covenants except for a defense that no Event of Default has occurred under the Purchase Agreement. 
 (f) The Collateral Agent hereby authorizes each Grantor to collect such Grantor’s Receivables, subject to the Collateral Agent’s direction and control after the occurrence and during the continuance of an Event of Default, and the
Collateral Agent may curtail or terminate said authority at any time after the occurrence and during the continuance of an Event of Default. If required by the Collateral Agent at any time after the occurrence and during the continuance of an Event
of Default, any payments of Receivables, when collected by any Grantor, (i) shall be forthwith (and, in any event, within two Business Days) deposited by such Grantor in the exact form received, duly indorsed by such Grantor to the Collateral
Agent if required, in a collateral account maintained under the sole dominion and control of the Collateral Agent, subject to withdrawal by the Collateral Agent for the account of the Secured Parties at its discretion, and (ii) until so turned
over, shall be held by such Grantor in trust for the Collateral Agent and the Secured Parties, segregated from other funds of such Grantor. Each such deposit of Proceeds of Receivables shall be accompanied by a report identifying in reasonable
detail the nature and source of the payments included in the deposit. 
 (g) At any time after the occurrence and during the
continuance of an Event of Default, at the Collateral Agent’s request, each Grantor shall deliver to the Collateral Agent all original and other documents evidencing, and relating to, the agreements and transactions that gave rise to the
Receivables, including, without limitation, all original orders, invoices and shipping receipts. 
 (h) At any time after the
occurrence and during the continuance of an Event of Default, each Grantor will cooperate with the Collateral Agent to establish a system of lockbox accounts, under the sole dominion and control of the Collateral Agent, into which all Receivables
shall be paid and from which all collected funds will be transferred to a Collateral Account. 
  

 19 

 (i) Upon the request of the Collateral Agent at any time after the occurrence and during
the continuance of an Event of Default, each Grantor hereby authorizes the Collateral Agent to notify each obligor on the Receivables that the Receivables have been assigned to the Collateral Agent for the ratable benefit of the Secured Parties as
Collateral hereunder and to instruct such obligor to make all payments in respect thereof directly to the Collateral Agent or to the Collateral Account or as otherwise directed by the Collateral Agent. 
 Section 10. Certain Waivers. Each Grantor waives, to the fullest extent permitted by law, (i) any right of redemption with respect to
the Collateral, whether before or after sale hereunder; and (ii) any right to require the Collateral Agent or any Secured Party (A) to proceed against any Person, (B) to exhaust any other collateral or security for any of the
Obligations, (C) to pursue any remedy in any Secured Party’s or Collateral Agent’s power, or (D) to make or give any presentments, demands for performance, notices of nonperformance, protests, notices of protests or notices of
dishonor in connection with any of the Collateral. 
 Section 11. Notices. All notices or other communications hereunder shall
be in writing (including by facsimile transmission) and mailed, sent or delivered to the respective parties hereto at or to their respective addresses or facsimile numbers set forth below their names on the signature pages hereof, or at or to such
other address or facsimile number as shall be designated by any party in a written notice to the other parties hereto. All such notices and other communications shall be effective (i) if delivered by hand, when delivered; (ii) if sent by
mail, upon the earlier of the date of receipt or five Business Days after deposit in the mail, first class (or air mail, with respect to communications to be sent to or from the United States); (iii) if sent by overnight mail, one day after
deposit with the overnight courier; and (iv) if sent by facsimile transmission, when sent so long as a valid confirmation is received by sender. 
 Section 12. No Waiver; Cumulative Remedies. No failure on the part of any Secured Party or the Collateral Agent to exercise, and no delay in exercising, any right, remedy, power or privilege under this
Agreement, the Purchase Agreement and the Related Documents shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, remedy, power or privilege preclude any other or further exercise thereof or the exercise of
any other right, remedy, power or privilege. The rights and remedies under this Agreement, the Purchase Agreement and the Related Documents are cumulative and not exclusive of any rights, remedies, powers and privileges that may otherwise be
available to such Secured Party or the Collateral Agent. 
 Section 13. Binding Effect. This Agreement shall be binding upon,
inure to the benefit of and be enforceable by any Grantor, any Secured Party, any Collateral Agent appointed hereunder and their respective successors and assigns. 
 Section 14. Governing Law and Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the law of the State of California, without regard to the choice of law rules thereof,
except to the extent the validity or perfection of the security interests hereunder, or the remedies hereunder, in respect of any Collateral are governed by the law of a jurisdiction other than California. 
 Section 15. Entire Agreement; Amendment and Waiver. This Agreement contains the entire agreement of the parties with respect to the subject
matter hereof and no amendment to this Agreement, or any waiver of any provision hereof, shall be effective unless it is in writing and signed by the Majority Secured Parties and (in the case of any amendment) each Grantor; except that no amendment,
waiver or consent shall, unless in writing and additionally signed by the Collateral Agent affect the rights or duties of the Collateral Agent under this Agreement. 
  

 20 

 Section 16. Severability. Whenever possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under all applicable laws and regulations. If, however, any provision of this Agreement shall be prohibited by or invalid under any such law or regulation in any jurisdiction, it shall, as to
such jurisdiction, be deemed modified to conform to the minimum requirements of such law or regulation, or, if for any reason it is not deemed so modified, it shall be ineffective and invalid only to the extent of such prohibition or invalidity
without affecting the remaining provisions of this Agreement, or the validity or effectiveness of such provision in any other jurisdiction. 
 Section 17. Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which
taken together shall constitute but one and the same agreement. 
 Section 18. Termination. This Agreement shall be terminated
upon indefeasible payment and performance in full of all Obligations. Upon termination, the Secured Parties and the Collateral Agent, as applicable, shall promptly, at the cost of the Grantors, execute and deliver to the Grantors such documents and
instruments reasonably requested by the Grantors as shall be necessary to evidence termination of all security interests given by the Grantors to the Secured Parties hereunder; provided, however, that the obligations under Section 4 hereof
shall survive such termination. 
 Section 19. Suretyship Waivers by Grantors, etc. 
 (a) Each Grantor agrees that its Obligations are irrevocable, absolute, independent and unconditional and shall not be affected by any
circumstance that constitutes a legal or equitable discharge of a guarantor or surety other than payment in full of the Obligations. In furtherance of the foregoing and without limiting the generality thereof, each Grantor agrees as follows:
(i) Secured Parties may from time to time, without notice or demand and without affecting the validity or enforceability of the Purchase Agreement or any Related Document or giving rise to any limitation, impairment or discharge of such
Grantor’s liability under the Purchase Agreement or any Related Document, (A) renew, extend, accelerate or otherwise change the time, place, manner or terms of payment of the Obligations, (B) settle, compromise, release or discharge,
or accept or refuse any offer of performance with respect to, or substitutions for, the Obligations or any agreement relating thereto and/or subordinate the payment of the same to the payment of any other obligations, (C) request and accept
guaranties of the Obligations and take and hold other security for the payment of the Obligations, (D) release, exchange, compromise, subordinate or modify, with or without consideration, any other security for payment of the Obligations, any
guaranties of the Obligations, or any other obligation of any Person with respect to the Obligations, (E) enforce and apply any other security now or hereafter held by or for the benefit of Secured Party in respect of the Obligations and direct
the order or manner of sale thereof, or exercise any other right or remedy that a Secured 

  

 21 

 
Party may have against any such security, as Secured Party in its discretion may determine consistent with the Purchase Agreement, the Related Documents and
any applicable security agreement, including foreclosure on any such security pursuant to one or more judicial or nonjudicial sales, whether or not every aspect of any such sale is commercially reasonable, and (F) exercise any other rights
available to such Secured Party under the Purchase Agreement and the Related Documents at law or in equity; and (ii) the Purchase Agreement, the Related Documents and the Obligations shall be valid and enforceable and shall not be subject to
any limitation, impairment or discharge for any reason (other than payment in full in cash of the Obligations), including, without limitation, the occurrence of any of the following, whether or not such Grantor shall have had notice or knowledge of
any of them: (A) any failure to assert or enforce or agreement not to assert or enforce, or the stay or enjoining, by order of court, by operation of law or otherwise, of the exercise or enforcement of, any claim or demand or any right, power
or remedy with respect to the Obligations or any agreement relating thereto, or with respect to any guaranty of or other security for the payment of the Obligations, (B) any waiver, amendment or modification of, or any consent to departure
from, any of the terms or provisions (including, without limitation, provisions relating to events of default) of the Purchase Agreement, any of the Related Documents or any agreement or instrument executed pursuant thereto, or of any guaranty or
other security for the Obligations, (C) the Obligations, or any agreement relating thereto, at any time being found to be illegal, invalid or unenforceable in any respect, (D) the application of payments received from any source to the
payment of indebtedness other than the Obligations, even though a Secured Party might have elected to apply such payment to any part or all of the Obligations, (E) any failure to perfect or continue perfection of a security interest in any
other collateral that secures any of the Obligations, (F) any defenses, set-offs or counterclaims that any Grantor may allege or assert against a Secured Party in respect of the Obligations, including, but not limited to, failure of
consideration, breach of warranty, payment, statute of frauds, statute of limitations, accord and satisfaction and usury, and (G) any other act or thing or omission, or delay to do any other act or thing, that may or might in any manner or to
any extent vary the risk of any Grantor as an obligor in respect of the Obligations. 
 (b) Each Grantor hereby waives, for
the benefit of the Secured Parties: (i) any right to require a Secured Party as a condition of payment or performance by such Grantor, to (A) proceed against such Grantor, any guarantor of the Obligations or any other Person,
(B) proceed against or exhaust any other security held from such Grantor, any guarantor of the Obligations or any other Person, (C) proceed against or have resort to any balance of any deposit account or credit on the books of Secured
Party of such Grantor or any other Person, or (D) pursue any other remedy in the power of Secured Party whatsoever; (ii) any defense arising by reason of the incapacity, lack of authority or any disability or other defense of such Grantor
including, without limitation, any defense based on or arising out of the lack of validity or the unenforceability of the Obligations or any agreement or instrument relating thereto or by reason of the cessation of the liability of such Grantor from
any cause other than payment in full of the Obligations; (iii) any defense based upon any statute or rule of law that provides that the obligation of a surety must be neither larger in amount nor in other respects more burdensome than that of
the principal; (iv) any defense based upon a Secured Party’s errors or omissions in the administration of the Obligations, except behavior that amounts to bad faith; (v) (A) any principles or provisions of law, statutory or
otherwise, that are or might be in conflict with the 

  

 22 

 
terms of the Purchase Agreement, any Related Document and any legal or equitable discharge of such Grantor’s obligations under the Purchase Agreement or
any Related Document, (B) the benefit of any statute of limitations affecting such Grantor’s liability hereunder or the enforcement of any Obligations, (C) any rights to set-offs, recoupments and counterclaims, and
(D) promptness, diligence and any requirement that a Secured Party protect, secure, perfect or insure any other security interest or lien or any property subject thereto; (vi) notices, demands, presentments, protests, notices of protest,
notices of dishonor and notices of any action or inaction, notices of default under the Purchase Agreement, any Related Document or any agreement or instrument related thereto, notices of any renewal, extension or modification of the Obligations or
any agreement related thereto, notices of any extension of credit to such Grantor and notices of any of the matters referred to in the preceding paragraph and any right to consent to any thereof; and (vii) to the fullest extent permitted by
law, any defenses or benefits that may be derived from or afforded by law that limit the liability of or exonerate guarantors or sureties, or that may conflict with the terms of the Purchase Agreement or any Related Document. 
 (c) As used in this Section 19(c), any reference to “the principal” includes each Grantor, and any reference to “the
creditor” includes each Secured Party. In accordance with Section 2856 of the California Civil Code (a) each Grantor waives any and all rights and defenses available to the Grantor by reason of Sections 2787 to 2855, inclusive, 2899
and 3433 of the California Civil Code. No other provision of this Agreement shall be construed as limiting the generality of any of the covenants and waivers set forth in this Section 19. 
 (d) Until the Obligations shall have been paid in full in cash, each Grantor shall withhold exercise of (i) any claim, right or
remedy, direct or indirect, that such Grantor now has or may hereafter have against the other Grantors or any of their assets in connection with the Purchase Agreement and the Related Documents or the performance by such Grantor of its obligations
under the Purchase Agreement and the Related Documents, in each case whether such claim, right or remedy arises in equity, under contract, by statute (including, without limitation, under California Civil Code Section 2847, 2848 or 2849), under
common law or otherwise and including without limitation (A) any right of subrogation, reimbursement or indemnification that a Grantor now has or may hereafter have against another Grantor, (B) any right to enforce, or to participate in,
any claim, right or remedy that a Secured Party now has or may hereafter have against any Grantor, and (C) any benefit of, and any right to participate in, any other collateral or security now or hereafter held by a Secured Party and
(ii) any right of contribution such Grantor may have against any other guarantor of the Obligations. Each Grantor further agrees that, to the extent the waiver of its rights of subrogation, reimbursement, indemnification and contribution as set
forth herein is found by a court of competent jurisdiction to be void or voidable for any reason, any rights of subrogation, reimbursement or indemnification such Grantor may have against any other Grantor or against any other collateral or
security, and any rights of contribution such Grantor may have against any such guarantor, shall be junior and subordinate to any rights a Secured Party may have against the other Grantors, to all right, title and interest a Secured Party may have
in any such other collateral or security, and to any right a Secured Party, may have against any such guarantor. 
  

 23 

 (e) No Secured Party shall have any obligation to disclose or discuss with any Grantor
its assessment, or such Grantor’s assessment, of the financial condition of any other Grantor. Each Grantor has adequate means to obtain information from the other Grantors on a continuing basis concerning the financial condition of the other
Grantors and their ability to perform their obligations under the Purchase Agreement and the Related Documents, and such Grantor assumes the responsibility for being and keeping informed of the financial condition of the other Grantors and of all
circumstances bearing upon the risk of nonpayment of the Obligations. Each Grantor hereby waives and relinquishes any duty on the part of a Secured Party to disclose any matter, fact or thing relating to the business, operations or condition of the
other Grantors now known or hereafter known by a Secured Party. 
 [Remainder of page intentionally left blank] 
  

 24 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement, as of the date first
above written. 
  

			
	GRANTORS:
	
	ANESIVA, INC.
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
		
	Address:	 	 
		
	 	 	 

  

			
	ALGORX PHARMACEUTICALS, INC.
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
		
	Address:	 	 
		
	 	 	 

 SIGNATURE PAGE TO PLEDGE, SECURITY 
 AND COLLATERAL AGENT AGREEMENT 

					
	COLLATERAL AGENT:
	
	ARCION THERAPEUTICS, INC.
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	

  

					
	SECURED PARTIES:
	
	ARCION THERAPEUTICS, INC.
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	

 SIGNATURE PAGE TO PLEDGE, SECURITY 
 AND COLLATERAL AGENT AGREEMENT 

 SCHEDULE 1 
 to the Pledge, Security and Collateral Agent Agreement 
 for Anesiva, Inc. 
  

	1.	Locations of Chief Executive Office and Other Locations, Including of Collateral 

  

	 	a.	Chief Executive Office and Principal Place of Business: 

  

	 	b.	Other locations where the Debtor conducts business or Collateral is kept: 

  

	2.	Trade Names and Trade Styles; Other Corporate, Trade or Fictitious Names, Etc. 

  

	3.	Bank Accounts 

  

	4.	Organizational Identification Number; Federal Employer Identification Number. 

  

	5.	State of Incorporation; Prior Names. 

  

	6.	Assets in Possession of Third Parties. The following are names and addresses of all persons or entities other than the Grantors, such as lessees, consignees,
warehousemen or purchasers of chattel paper, which have possession or are intended to have possession of any of the Collateral consisting of instruments, chattel paper, inventory or equipment: 

  

	7.	Existing Security Interests. The Grantors’ assets are subject to the following security interest of Persons other than the Collateral Agent:

  

	8.	Tax Assessments. The following tax assessments are currently outstanding and unpaid: 

  

	9.	Guaranties. The Grantors have directly or indirectly guaranteed the following obligations of third parties: 

  

	10.	Subsidiaries. The Grantors have the following subsidiaries (list jurisdiction and date of incorporation, federal employer identification number, type and value of
assets): 

  

	11.	Securities; Instruments. The following is a complete list of all stocks, bonds, debentures, notes and other securities and investment property owned by the Grantor
(provide name of issuer, whether certificated or uncertificated, certificate no. (if applicable), number of shares): 

  

	12.	Securities Accounts: The following is a complete list of all securities accounts maintained by the Grantors (provide name and address of brokerage firm, type
of account and account number): 

  

	13.	Pledged Stock: 

  

 S-1-1 

 SCHEDULE 2 
 to the Security Agreement 
 for Anesiva, Inc. 
  

	1.	Patents and Patent Applications 

  

	2.	Copyrights and Copyright Applications 

  

	3.	Mask Works and Mask Work Applications 

  

	4.	Trademarks, Service Marks and Trade Names and Trademark, Service Mark and Trade Name Applications 

  

 S-2-1 

 SCHEDULE 3 
 Business Locations and Locations of Collateral 
 for Anesiva, Inc. 

 SCHEDULE 1 
 to the Pledge, Security and Collateral Agent Agreement 
 for AlgoRx Pharmaceuticals, Inc.

  

	12.	Locations of Chief Executive Office and Other Locations, Including of Collateral 

  

	 	a.	Chief Executive Office and Principal Place of Business: 

  

	 	b.	Other locations where the Debtor conducts business or Collateral is kept: 

  

	13.	Trade Names and Trade Styles; Other Corporate, Trade or Fictitious Names, Etc. 

  

	14.	Bank Accounts 

  

	15.	Organizational Identification Number; Federal Employer Identification Number. 

  

	16.	State of Incorporation; Prior Names. 

  

	17.	Assets in Possession of Third Parties. The following are names and addresses of all persons or entities other than the Grantors, such as lessees, consignees,
warehousemen or purchasers of chattel paper, which have possession or are intended to have possession of any of the Collateral consisting of instruments, chattel paper, inventory or equipment: 

  

	18.	Existing Security Interests. The Grantors’ assets are subject to the following security interest of Persons other than the Collateral Agent:

  

	19.	Tax Assessments. The following tax assessments are currently outstanding and unpaid: 

  

	20.	Guaranties. The Grantors have directly or indirectly guaranteed the following obligations of third parties: 

  

	21.	Subsidiaries. The Grantors have the following subsidiaries (list jurisdiction and date of incorporation, federal employer identification number, type and value of
assets): 

  

	22.	Securities; Instruments. The following is a complete list of all stocks, bonds, debentures, notes and other securities and investment property owned by the Grantor
(provide name of issuer, whether certificated or uncertificated, certificate no. (if applicable), number of shares): 

  

	12.	Securities Accounts: The following is a complete list of all securities accounts maintained by the Grantors (provide name and address of brokerage firm, type
of account and account number): 

  

	13.	Pledged Stock: 

  

 S-1-1 

 SCHEDULE 2 
 to the Security Agreement 
 for AlgoRx Pharmaceuticals, Inc. 
  

	5.	Patents and Patent Applications 

  

	6.	Copyrights and Copyright Applications 

  

	7.	Mask Works and Mask Work Applications 

  

	8.	Trademarks, Service Marks and Trade Names and Trademark, Service Mark and Trade Name Applications 

  

 S-2-1 

 SCHEDULE 3 
 Business Locations and Locations of Collateral 
 for AlgoRx Pharmaceuticals, Inc. 

 EXHIBIT C 
 GUARANTY 
 This Guaranty is entered into as of May 18, 2009 by AlgoRx Pharmaceuticals,
Inc., a Delaware corporation (the “Guarantor”), in favor of and for the benefit of Arcion Therapeutics, Inc., a Delaware corporation (together with its successors and assignees, the “Beneficiary”) under that certain
Secured Note Purchase Agreement, dated as of May 18, 2009, by and among Anesiva, Inc., a Delaware corporation (the “Company”), and the Beneficiary (said Secured Note Purchase Agreement, as it may hereafter be amended,
supplemented or otherwise modified from time to time, being the “Purchase Agreement;” capitalized terms defined therein and not otherwise defined herein being used herein as therein defined). 
 1. Guaranty. (a) In order to induce the Beneficiary to extend credit to the Company pursuant to the Purchase Agreement,
the Guarantor irrevocably and unconditionally guaranties, as primary obligor and not merely as surety, the due and punctual payment in full of all Guarantied Amounts (as hereinafter defined) when the same shall become due, whether at stated
maturity, by acceleration, demand or otherwise (including amounts that would become due but for the operation of the automatic stay under Section 362(a) of the Bankruptcy Code). The term “Guarantied Amounts” is used herein in
its most comprehensive sense and includes any and all obligations of Company in respect of notes, advances, borrowings, loans, debts, interest, fees, costs, expenses (including, without limitation, legal fees and expenses of counsel and allocated
costs of internal counsel), indemnities and liabilities of whatsoever nature now or hereafter made, incurred or created, whether absolute or contingent, liquidated or unliquidated, whether due or not due, and however arising under or in connection
with the Purchase Agreement, the Notes, this Guaranty and the other Related Documents, including those arising under successive borrowing transactions under the Purchase Agreement which shall either continue such obligations of the Company or from
time to time renew them after they have been satisfied. 
 The Guarantor acknowledges that the Guarantied Amounts are being
incurred for and will inure to the benefit of the Guarantor. 
 Any returns on any portion of the Guarantied Amounts that
accrues after the commencement of any proceeding, voluntary or involuntary, involving the bankruptcy, insolvency, receivership, reorganization, liquidation or arrangement of the Company (or, if returns on any portion of the Guarantied Amounts ceases
to accrue by operation of law by reason of the commencement of said proceeding, such returns as would have accrued on such portion of the Guarantied Amounts if said proceeding had not been commenced) shall be included in the Guarantied Amounts
because it is the intention of the Guarantor and the Beneficiary that the Guarantied Amounts should be determined without regard to any rule of law or order that may relieve the Company of any portion of such Guarantied Amounts. 

 In the event that all or any portion of the Guarantied Amounts is paid by the Company,
the obligations of the Guarantor hereunder shall continue and remain in full force and effect or be reinstated, as the case may be, in the event that all or any part of such payment(s) is rescinded or recovered directly or indirectly from the
Beneficiary as a preference, fraudulent transfer or otherwise, and any such payments that are so rescinded or recovered shall constitute Guarantied Amounts. 
 Subject to the other provisions of this Section 1, upon the failure of the Company to pay any of the Guarantied Amounts when and as
the same shall become due, the Guarantor will upon demand pay, or cause to be paid, in cash, to the Beneficiary, an amount equal to the aggregate of the unpaid Guarantied Amounts. Such payments shall be made in accordance with the applicable
provisions of the Purchase Agreement. 
 (b) Anything contained in this Guaranty to the contrary notwithstanding, the
obligations of the Guarantor under this Guaranty and the other Related Documents shall be limited to a maximum aggregate amount equal to the largest amount that would not render its obligations hereunder subject to avoidance as a fraudulent transfer
or conveyance under Section 548 of Title 11 of the United States Code or any applicable provisions of comparable state or foreign law (collectively, the “Fraudulent Transfer Laws”), in each case after giving effect to all other
liabilities of the Guarantor, contingent or otherwise, that are relevant under the Fraudulent Transfer Laws (specifically excluding, however, any liabilities of the Guarantor (x) in respect of intercompany indebtedness to the Company or other
affiliates of the Company to the extent that such indebtedness would be discharged in an amount equal to the amount paid by the Guarantor hereunder and (y) under any guaranty of subordinated indebtedness which guaranty contains a limitation as
to maximum amount similar to that set forth in this Section 1(b), pursuant to which the liability of the Guarantor hereunder is included in the liabilities taken into account in determining such maximum amount) and after giving effect as assets
to the value (as determined under the applicable provisions of the Fraudulent Transfer Laws) of any rights to subrogation, reimbursement, indemnification or contribution of the Guarantor pursuant to applicable law or pursuant to the terms of any
agreement. 
 (c) The Guarantor under this Guaranty, and each guarantor under other guaranties, if any, relating to the
Purchase Agreement (the “Related Guaranties”) that contain a contribution provision similar to that set forth in this Section 1(c), together desire to allocate among themselves (collectively, the “Contributing
Guarantors”), in a fair and equitable manner, their obligations arising under this Guaranty and the Related Guaranties. Accordingly, in the event any payment or distribution is made on any date by the Guarantor under this Guaranty or a
guarantor under a Related Guaranty, the Guarantor or such other guarantor shall be entitled to a contribution from each of the other Contributing Guarantors in the maximum amount permitted by law so as to maximize the aggregate amount of the
Guarantied Amounts paid to the Beneficiary. 
 2. Guaranty Absolute; Continuing Guaranty. The obligations of the
Guarantor hereunder are irrevocable, absolute, independent and unconditional and shall not be affected by any circumstance that constitutes a legal or equitable discharge of a guarantor or surety other than payment in full of the Guarantied Amounts.
In furtherance of the foregoing, and without limiting the generality thereof, the Guarantor agrees that: (a) this Guaranty is a guaranty of payment when due and not of collectibility; (b) the 

  

 2 

 
Beneficiary may enforce this Guaranty upon the occurrence and during the continuance of an Event of Default under the Purchase Agreement notwithstanding the
existence of any dispute between the Company and the Beneficiary with respect to the existence of such event; (c) the obligations of the Guarantor hereunder are independent of the obligations of the Company under the Purchase Agreement and the
Related Documents and the obligations of any other guarantor of obligations of the Company and a separate action or actions may be brought and prosecuted against the Guarantor whether or not any action is brought against the Company or any of such
other guarantors and whether or not the Company is joined in any such action or actions; and (d) the Guarantor’s payment of a portion, but not all, of the Guarantied Amounts shall in no way limit, affect, modify or abridge the
Guarantor’s liability for any portion of the Guarantied Amounts that has not been paid. This Guaranty is a continuing guaranty and shall be binding upon the Guarantor and its successors and assigns, and the Guarantor irrevocably waives any
right (including, without limitation, any such right arising under California Civil Code Section 2815) to revoke this Guaranty as to future transactions giving rise to any Guarantied Amounts. 
 3. Actions by Beneficiary. The Beneficiary may from time to time, without notice or demand and without affecting the validity or
enforceability of this Guaranty or giving rise to any limitation, impairment or discharge of the Guarantor’s liability hereunder, (a) renew, extend, accelerate or otherwise change the time, place, manner or terms of payment of the
Guarantied Amounts; (b) settle, compromise, release or discharge, or accept or refuse any offer of performance with respect to, or substitutions for, the Guarantied Amounts or any agreement relating thereto and/or subordinate the payment of the
same to the payment of any other obligations; (c) request and accept other guaranties of the Guarantied Amounts and take and hold security for the payment of this Guaranty or the Guarantied Amounts; (d) release, exchange, compromise,
subordinate or modify, with or without consideration, any security for payment of the Guarantied Amounts, any other guaranties of the Guarantied Amounts, or any other obligation of any Person with respect to the Guarantied Amounts; (e) enforce
and apply any security now or hereafter held by or for the benefit of the Beneficiary in respect of this Guaranty or the Guarantied Amounts and direct the order or manner of sale thereof, or exercise any other right or remedy that the Beneficiary,
may have against any such security, as the Beneficiary in its discretion may determine consistent with the Purchase Agreement, the Related Documents and any applicable security agreement, including foreclosure on any such security pursuant to one or
more judicial or nonjudicial sales, whether or not every aspect of any such sale is commercially reasonable; and (f) exercise any other rights available to the Beneficiary, under the Purchase Agreement or the Related Documents, at law or in
equity. 
 4. No Discharge. This Guaranty and the obligations of the Guarantor hereunder shall be valid and enforceable
and shall not be subject to any limitation, impairment or discharge for any reason (other than payment in full of the Guarantied Amounts), including without limitation the occurrence of any of the following, whether or not the Guarantor shall have
had notice or knowledge of any of them: (a) any failure to assert or enforce or agreement not to assert or enforce, or the stay or enjoining, by order of court, by operation of law or otherwise, of the exercise or enforcement of, any claim or

  

 3 

 
demand or any right, power or remedy with respect to the Guarantied Amounts or any agreement relating thereto, or with respect to any other guaranty of or
security for the payment of the Guarantied Amounts; (b) any waiver or modification of, or any consent to departure from, any of the terms or provisions of the Purchase Agreement, any of the Related Documents or any agreement or instrument
executed pursuant thereto, or of any other guaranty or security for the Guarantied Amounts; (c) the Guarantied Amounts, or any agreement relating thereto, at any time being found to be illegal, invalid or unenforceable in any respect;
(d) the application of payments received from any source to the payment of indebtedness other than the Guarantied Amounts, even though the Beneficiary, might have elected to apply such payment to any part or all of the Guarantied Amounts;
(e) any failure to perfect or continue perfection of a security interest in any collateral that secures any of the Guarantied Amounts; (f) any defenses, set-offs or counterclaims that the Company may assert against the Beneficiary in
respect of the Guarantied Amounts, including, but not limited to, failure of consideration, breach of warranty, payment, statute of frauds, statute of limitations, accord and satisfaction and usury; and (g) any other act or thing or omission,
or delay to do any other act or thing, that may or might in any manner or to any extent vary the risk of the Guarantor as an obligor in respect of the Guarantied Amounts. 
 5. Waivers. The Guarantor waives, for the benefit of the Beneficiary: (a) any right to require the Beneficiary, as a condition
of payment or performance by the Guarantor, to (i) proceed against the Company, any other guarantor of the Guarantied Amounts or any other Person, (ii) proceed against or exhaust any security held from the Company, any other guarantor of
the Guarantied Amounts or any other Person, (iii) proceed against or have resort to any balance of any deposit account or credit on the books of the Beneficiary in favor of the Company or any other Person, or (iv) pursue any other remedy
in the power of the Beneficiary; (b) any defense arising by reason of the incapacity, lack of authority or any disability or other defense of the Company including, without limitation, any defense based on or arising out of the lack of validity
or the unenforceability of the Guarantied Amounts or any agreement or instrument relating thereto or by reason of the cessation of the liability of the Company from any cause other than payment in full of the Guarantied Amounts; (c) any defense
based upon any statute or rule of law that provides that the obligation of a surety must be neither larger in amount nor in other respects more burdensome than that of the principal; (d) any defense based upon the Beneficiary’s errors or
omissions in the administration of the Guarantied Amounts, except behavior that amounts to bad faith; (e) (i) any principles or provisions of law, statutory or otherwise, that are or might be in conflict with the terms of this Guaranty and
any legal or equitable discharge of the Guarantor’s obligations hereunder, (ii) the benefit of any statute of limitations affecting the Guarantor’s liability hereunder or the enforcement hereof, (iii) any rights to set-offs,
recoupments and counterclaims and (iv) promptness, diligence and any requirement that the Beneficiary protect, secure, perfect or insure any Lien or any property subject thereto; (f) notices, demands, presentments, protests, notices of
protest, notices of dishonor and notices of any action or inaction, including acceptance of this Guaranty, notices of default under the Purchase Agreement or any agreement or instrument related thereto, notices of any renewal, extension or
modification of the Guarantied Amounts or any agreement related thereto, notices of any extension of credit to the Company and notices of any of the matters referred to in Sections 3 and 4 and any right to consent to any thereof; and (g) to the
fullest extent permitted by law, any defenses or benefits that may be derived from or afforded by law that limit the liability of or exonerate guarantors or sureties, or that may conflict with the terms of this Guaranty. 
  

 4 

 As used in this paragraph, any reference to “the principal” includes the
Company, and any reference to “the creditor” includes the Beneficiary. In accordance with Section 2856 of the California Civil Code, the Guarantor waives any and all rights and defenses available to the Guarantor by reason of Sections
2787 to 2855, inclusive, of the California Civil Code, including, without limitation, any and all rights or defenses the Guarantor may have because the Guarantied Amounts are or may be secured by real property. This means, among other things:
(1) the creditor may collect from the Guarantor without first foreclosing on any real or personal property collateral pledged by the principal and (2) if the creditor forecloses on any real property collateral pledged by the principal:
(A) the amount of the Guarantied Amounts may be reduced only by the price for which the collateral is sold at the foreclosure sale, even if the collateral is worth more than the sale price and (B) the creditor may collect from the
Guarantor even if the creditor, by foreclosing on the real property collateral, has destroyed any right the Guarantor may have to collect from the principal. This is an unconditional and irrevocable waiver of any right and defenses the Guarantor may
have because the Guarantied Amounts are secured by real property. These rights and defenses include, but are not limited to, any rights and defenses based upon Section 580a, 580b, 580d or 726 of the California Code of Civil Procedure. The
Guarantor also waives all rights and defenses arising out of an election of remedies by the creditor, even though that election of remedies, such as a nonjudicial foreclosure with respect to security for a Guarantied Amount, has destroyed the
Guarantor’s rights of subrogation and reimbursement against the principal by the operation of Section 580d of the Code of Civil Procedure or otherwise; and even though that election of remedies by the creditor, such as nonjudicial
foreclosure with respect to security for an obligation of any other guarantor of any of the Guarantied Amounts, has destroyed the Guarantor’s rights of contribution against such other guarantor. No other provision of this Guaranty shall be
construed as limiting the generality of any of the covenants and waivers set forth in this paragraph. 
 6.
Guarantor’s Rights of Subrogation, Contribution, Etc.; Subordination of Other Obligations. Until the Guarantied Amounts shall have been paid in full, the Guarantor shall withhold exercise of (a) any claim, right or remedy, direct or
indirect, that the Guarantor now has or may hereafter have against the Company or any of its assets in connection with this Guaranty or the performance by the Guarantor of its obligations hereunder, in each case whether such claim, right or remedy
arises in equity, under contract, by statute (including without limitation under California Civil Code Section 2847, 2848 or 2849), under common law or otherwise and including, without limitation, (i) any right of subrogation,
reimbursement or indemnification that the Guarantor now has or may hereafter have against the Company; (ii) any right to enforce, or to participate in, any claim, right or remedy that the Beneficiary now has or may hereafter have against the
Company; and (iii) any benefit of, and any right to participate in, any collateral or security now or hereafter held by the Beneficiary and (b) any right of contribution the Guarantor now has or may hereafter have against any other
guarantor of 

  

 5 

 
any of the Guarantied Amounts. The Guarantor further agrees that, to the extent the agreement to withhold the exercise of its rights of subrogation,
reimbursement, indemnification and contribution as set forth herein is found by a court of competent jurisdiction to be void or voidable for any reason, any rights of subrogation, reimbursement or indemnification the Guarantor may have against the
Company or against any collateral or security, and any rights of contribution the Guarantor may have against any such other guarantor, shall be junior and subordinate to any rights the Beneficiary may have against the Company, to all right, title
and interest the Beneficiary may have in any such collateral or security, and to any right the Beneficiary may have against such other guarantor. 
 Any indebtedness of the Company now or hereafter held by the Guarantor is subordinated in right of payment to the Guarantied Amounts, and any such indebtedness of the Company to the Guarantor collected or received by
the Guarantor after an Event of Default has occurred and is continuing, and any amount paid to the Guarantor on account of any subrogation, reimbursement, indemnification or contribution rights referred to in the preceding paragraph when all
Guarantied Amounts have not been paid in full, shall be held in trust for the Beneficiary and shall forthwith be paid over to the Beneficiary to be credited and applied against the Guarantied Amounts. 
 7. Expenses. The Guarantor agrees to pay, or cause to be paid, on demand, and to save the Beneficiary harmless against liability
for, (i) any and all costs and expenses (including fees, costs of settlement and disbursements of counsel and allocated costs of internal counsel) incurred or expended by the Beneficiary in connection with the enforcement of or preservation of
any rights under this Guaranty and (ii) any and all costs and expenses (including those arising from rights of indemnification) required to be paid by the Guarantor under the provisions of the Purchase Agreement or any Related Document.

 8. Financial Condition of Company. The Beneficiary shall not have any obligation, and the Guarantor waives any duty
on the part of the Beneficiary, to disclose or discuss with the Guarantor its assessment, or the Guarantor’s assessment, of the financial condition of the Company or any matter or fact relating to the business, operations or condition of the
Company. The Guarantor has adequate means to obtain information from the Company on a continuing basis concerning the financial condition of the Company and its ability to perform its obligations under the Purchase Agreement and the Related
Documents, and the Guarantor assumes the responsibility for being and keeping informed of the financial condition of the Company and of all circumstances bearing upon the risk of nonpayment of the Guarantied Amounts. 
 9. Representations and Warranties. The Guarantor makes, for the benefit of the Beneficiary, each of the representations and
warranties made in the Purchase Agreement by the Company as to the Guarantor, its assets, financial condition, operations, organization, legal status, business and the Related Documents to which it is a party. 
  

 6 

 10. Covenants. The Guarantor agrees that, so long as any part of the Guarantied
Amounts shall remain unpaid, the Guarantor will, unless the Majority Investors shall otherwise consent in writing, perform or observe, and cause its Subsidiaries to perform or observe, all of the terms, covenants and agreements that the Purchase
Agreement and the Related Documents state that the Company is to cause the Guarantor and such Subsidiaries to perform or observe. 
 11. Set Off. In addition to any other rights the Beneficiary may have under law or in equity, if any amount shall at any time be due and owing by the Guarantor to the Beneficiary under this Guaranty, the Beneficiary is authorized at
any time or from time to time, without notice (any such notice being expressly waived), to set off and to appropriate and to apply any and all deposits (general or special, including, but not limited to, indebtedness evidenced by certificates of
deposit, whether matured or unmatured) and any other indebtedness of the Beneficiary owing to the Guarantor and any other property of the Guarantor held by the Beneficiary to or for the credit or the account of the Guarantor against and on account
of the Guarantied Amounts and liabilities of the Guarantor to the Beneficiary under this Guaranty. 
 12. Amendments and
Waivers. No amendment, modification, termination or waiver of any provision of this Guaranty, and no consent to any departure by the Guarantor therefrom, shall in any event be effective without the written concurrence of the Majority Investors
and, in the case of any such amendment or modification, the Guarantor. Any such waiver or consent shall be effective only in the specific instance and for the specific purpose for which it was given. Any amendment or waiver effected in accordance
with this Section 12 shall be binding upon the Beneficiary and each other holder of any Notes purchased under the Purchase Agreement at the time outstanding, each future holder of all such Notes and the Guarantor. 
 13. Miscellaneous. It is not necessary for the Beneficiary to inquire into the capacity or powers of the Guarantor or the Company
or the officers, directors or any agents acting or purporting to act on behalf of any of them. 
 The rights, powers and
remedies given to the Beneficiary by this Guaranty are cumulative and shall be in addition to and independent of all rights, powers and remedies given to the Beneficiary by virtue of any statute or rule of law or in the Purchase Agreement or any of
the Related Documents or any agreement between the Guarantor and the Beneficiary or between the Company and the Beneficiary. Any forbearance or failure to exercise, and any delay by the Beneficiary in exercising, any right, power or remedy hereunder
shall not impair any such right, power or remedy or be construed to be a waiver thereof, nor shall it preclude the further exercise of any such right, power or remedy. 
 In case any provision in or obligation under this Guaranty shall be invalid, illegal or unenforceable in any jurisdiction, the validity,
legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 
 THIS GUARANTY AND THE RIGHTS AND OBLIGATIONS OF THE GUARANTOR AND THE BENEFICIARY HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE
CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF CALIFORNIA, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES. 
  

 7 

 This Guaranty shall inure to the benefit of the Beneficiary and their respective
successors and assigns. 
 ALL JUDICIAL PROCEEDINGS BROUGHT AGAINST THE GUARANTOR ARISING OUT OF OR RELATING TO THIS GUARANTY
MAY BE BROUGHT IN ANY STATE COURT OF COMPETENT JURISDICTION IN SAN FRANCISCO COUNTY, STATE OF CALIFORNIA, OR IN ANY FEDERAL COURT OF COMPETENT JURISDICTION IN THE NORTHERN DISTRICT FOR THE STATE OF CALIFORNIA, AND BY EXECUTION AND DELIVERY OF THIS
GUARANTY THE GUARANTOR ACCEPTS FOR ITSELF AND IN CONNECTION WITH ITS PROPERTIES, GENERALLY AND UNCONDITIONALLY, THE NONEXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS AND IRREVOCABLY AGREES TO BE BOUND
BY ANY JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS GUARANTY. The Guarantor agrees that service of all process in any such proceeding in any such court may be made by registered or certified mail, return receipt requested, to the Guarantor at
its address set forth below its signature hereto, such service being acknowledged by the Guarantor to be sufficient for personal jurisdiction in any action against the Guarantor in any such court and to be otherwise effective and binding service in
every respect. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of the Beneficiary to bring proceedings against the Guarantor in the courts of any other jurisdiction. 
 THE GUARANTOR AND THE BENEFICIARY EACH AGREE TO WAIVE ITS RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR
ARISING OUT OF THIS GUARANTY. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT
CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THE GUARANTOR AND THE BENEFICIARY EACH (I) ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT FOR THE GUARANTOR AND THE BENEFICIARY TO ENTER INTO A
BUSINESS RELATIONSHIP, THAT THE GUARANTOR AND THE BENEFICIARY HAVE ALREADY RELIED ON THIS WAIVER IN ENTERING INTO THIS GUARANTY AND THAT EACH WILL CONTINUE TO RELY ON THIS WAIVER IN THEIR RELATED FUTURE DEALINGS, AND (II) FURTHER WARRANT AND
REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED
EITHER ORALLY OR IN WRITING, AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS OF THIS GUARANTY. In the event of litigation, this Guaranty may be filed as a written consent to a trial by the court.

  

 8 

 14. Counterparts. This Guaranty may be executed in any number of counterparts and
by the different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed to be an original for all purposes; but all such counterparts together shall constitute but one and the same instrument.

 [Remainder of page intentionally left blank] 
  

 9 

 IN WITNESS WHEREOF, the Guarantor and the Beneficiary have caused this Guaranty to be duly
executed and delivered by their respective officers thereunto duly authorized as of the date first written above. 
  

					
	GUARANTOR:
	
	ALGORX PHARMACEUTICALS, INC.
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	
		
	Address:	 	 
			
	 	 	 	 	 

 [Signature Page to Guaranty] 

					
	BENEFICIARY:
	
	ARCION THERAPEUTICS, INC.
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	

 [Signature Page to Guaranty]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]